10-Q

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

0001193125-16-448574.txt : 20160203 0001193125-16-448574.hdr.sgml : 20160203 20160203095432 ACCESSION NUMBER: 0001193125-16-448574 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 81 CONFORMED PERIOD OF REPORT: 20151231 FILED AS OF DATE: 20160203 DATE AS OF CHANGE: 20160203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MYRIAD GENETICS INC CENTRAL INDEX KEY: 0000899923 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 870494517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-26642 FILM NUMBER: 161383457 BUSINESS ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 MAIL ADDRESS: STREET 1: 320 WAKARA WAY CITY: SALT LAKE CITY STATE: UT ZIP: 84108 10-Q 1 d105198d10q.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2015

¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 0-26642

MYRIAD GENETICS, INC.

(Exact name of registrant as specified in its charter)


Delaware		87-0494517
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

320 Wakara Way, Salt Lake City, UT		84108
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (801) 584-3600

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “accelerated filer,” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Check one:

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

As of January 29, 2016 the registrant had 71,252,152 shares of $0.01 par value common stock outstanding.

MYRIAD GENETICS, INC.

INDEX TO FORM 10-Q


		Page
PART I - Financial Information

Item 1.	Financial Statements

	Condensed Consolidated Balance Sheets (Unaudited) as of December 31, 2015 and June 30, 2015		3

	Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended December 31, 2015 and 2014		4

	Condensed Consolidated Statement of Comprehensive Income (Unaudited) for the three and six months ended December 31, 2015 and 2014		5

	Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended December 31, 2015 and 2014		6

	Notes to Condensed Consolidated Financial Statements (Unaudited)		7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		17

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		22

Item 4.	Controls and Procedures		23

PART II - Other Information

Item 1.	Legal Proceedings		24

Item 1A.	Risk Factors		24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		24

Item 3.	Defaults Upon Senior Securities		24

Item 4.	Mine Safety Disclosures		24

Item 5.	Other Information		24

Item 6.	Exhibits		24

Signatures			26

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(In millions)


	December 31, 2015			June 30, 2015
ASSETS
Current assets:
Cash and cash equivalents	$	134.7		$	64.1
Marketable investment securities		84.6			80.7
Prepaid expenses		9.7			12.5
Inventory		29.1			25.1
Trade accounts receivable, less allowance for doubtful accounts of $6.2 December 31, 2015 and $7.6 June 30, 2015		84.3			85.8
Deferred taxes		—			13.5
Prepaid taxes		28.0			—
Other receivables		5.1			1.9

Total current assets		375.5			283.6

Property, plant and equipment, net		61.7			67.2
Long-term marketable investment securities		66.2			40.6
Intangibles, net		186.3			192.6
Goodwill		177.0			177.2
Other assets		5.0			5.0

Total assets	$	871.7		$	766.2

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	16.5		$	21.1
Accrued liabilities		47.9			46.1
Deferred revenue		1.5			1.5

Total current liabilities		65.9			68.7

Unrecognized tax benefits		27.9			26.4
Other long-term liabilities		6.8			8.8
Long-term deferred taxes		0.3			0.2

Total liabilities		100.9			104.1

Commitments and contingencies
Stockholders’ equity:
Common stock, 71.6 and 68.9 shares outstanding at December 31, 2015 and June 30, 2015 respectively		0.7			0.7
Additional paid-in capital		847.8			745.4
Accumulated other comprehensive loss		(9.1	)		(7.0	)
Accumulated deficit		(68.6	)		(77.0	)

Total stockholders’ equity		770.8			662.1

Total liabilities and stockholders’ equity	$	871.7		$	766.2

See accompanying notes to condensed consolidated financial statements.

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

(In millions, except per share amounts)


	Three months ended December 31,					Six months ended December 31,
	2015			2014		2015			2014
Molecular diagnostic testing	$	182.6		$	179.2	$	354.5		$	343.6
Pharmaceutical and clinical services		10.7			5.2		22.3			9.6

Total revenue		193.3			184.4		376.8			353.2
Costs and expenses:
Cost of molecular diagnostic testing		34.1			35.1		65.0			67.8
Cost of pharmaceutical and clinical services		6.5			2.8		12.1			4.9
Research and development expense		16.7			17.5		33.9			40.1
Selling, general, and administrative expense		90.8			92.7		177.3			178.1

Total costs and expenses		148.1			148.1		288.3			290.9

Operating income		45.2			36.3		88.5			62.3
Other income (expense):
Interest income		0.1			0.1		0.2			0.1
Other		(0.3	)		1.5		(0.1	)		1.4

Total other income (expense):		(0.2	)		1.6		0.1			1.5

Income before income tax		45.0			37.9		88.6			63.8
Income tax provision		14.7			13.9		31.6			23.8

Net income	$	30.3		$	24.0	$	57.0		$	40.0

Earnings per share:
Basic	$	0.43		$	0.33	$	0.82		$	0.55
Diluted	$	0.41		$	0.32	$	0.78		$	0.53

Weighted average shares outstanding:
Basic		70.5			72.5		69.6			72.6
Diluted		73.8			75.4		73.1			75.8

See accompanying notes to condensed consolidated financial statements.

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(In millions)


	Three months ended December 31,						Six months ended December 31,
	2015			2014			2015			2014
Net income	$	30.3		$	24.0		$	57.0		$	40.0
Unrealized gain (loss) on available-for-sale securities, net of tax		(0.2	)		(0.1	)		(0.1	)		(0.3	)
Change in foreign currency translation adjustment, net of tax		(1.8	)		(1.7	)		(2.0	)		(2.4	)

Comprehensive income	$	28.3		$	22.2		$	54.9		$	37.3

See accompanying notes to condensed consolidated financial statements.

MYRIAD GENETICS, INC.

AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(In millions)


	Six months ended December 31,
	2015			2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$	57.0		$	40.0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		13.5			12.0
Gain on disposition of assets		(0.4	)		—
Share-based compensation expense		16.3			19.0
Bad debt expense		14.5			14.0
Deferred income taxes		29.8			1.9
Unrecognized tax benefits		1.5			1.1
Excess tax benefit from share-based compensation		(16.1	)		(2.6	)
Gain on remeasurement of foreign currency		—			(0.5	)
Changes in assets and liabilities:
Prepaid expenses		2.8			(0.8	)
Trade accounts receivable		(11.1	)		(13.9	)
Other receivables		(5.3	)		(1.6	)
Inventory		(4.1	)		3.7
Prepaid taxes		(28.0	)		8.0
Accounts payable		(4.1	)		(6.2	)
Accrued liabilities		(0.5	)		(15.2	)
Deferred revenue		—			0.7

Net cash provided by operating activities		65.8			59.6

CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures		(2.1	)		(17.5	)
Restricted cash		—			(21.6	)
Purchases of marketable investment securities		(100.7	)		(22.6	)
Proceeds from maturities and sales of marketable investment securities		71.3			80.5

Net cash provided by (used in) investing activities		(31.5	)		18.8

CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from common stock issued under share-based compensation plans		84.9			20.2
Excess tax benefit from share-based compensation		16.1			2.6
Repurchase and retirement of common stock		(62.9	)		(103.9	)

Net cash provided by (used in) financing activities		38.1			(81.1	)

Effect of foreign exchange rates on cash and cash equivalents		(1.8	)		(2.4	)
Net increase (decrease) in cash and cash equivalents		70.6			(5.1	)
Cash and cash equivalents at beginning of the period		64.1			64.8

Cash and cash equivalents at end of the period	$	134.7		$	59.7

See accompanying notes to condensed consolidated financial statements.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(Dollars and shares in millions, except per share data)

(1)

BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements have been prepared by Myriad Genetics, Inc. (the “Company”) in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (“SEC”). The condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The condensed consolidated financial statements herein should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2015, included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2015. Operating results for the three and six months ended December 31, 2015 may not necessarily be indicative of results to be expected for any other interim period or for the full year.

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

(2)

ACQUISITIONS

German Clinic

On February 27, 2015, the Company completed the acquisition of privately-held Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) approximately 15 miles from the Company’s European laboratories in Munich, Germany. The cash paid and preliminary total consideration transferred to acquire the Clinic was $20.1.

Total consideration transferred was allocated to tangible assets acquired and liabilities assumed based on their preliminary fair values at the acquisition date as set forth below. The Company believes acquisition of the Clinic should facilitate the Company’s penetration into the German molecular diagnostic market. The Clinic will allow the Company to directly negotiate reimbursement with government and private insurance providers for its tests in the German market and collaborate with hospitals and physician groups. These factors contributed to consideration transferred in excess of the fair value of the Clinic’s net tangible and intangible assets acquired, resulting in the Company recording goodwill in connection with the transaction. Under German tax law the goodwill related to the purchase of the clinic is deductible and will be amortized for tax purposes over 15 years.

Management estimated the fair value of tangible and intangible assets and liabilities in accordance with the applicable accounting guidance for business combinations and utilized the services of third-party valuation consultants. The preliminary allocation of the consideration transferred is subject to potential adjustments primarily due to tax-related matters, including tax basis of acquired assets and liabilities in the foreign jurisdiction, and third party valuations of acquired assets and liabilities, including actuarial analysis of pension assets and liabilities and fair value of equipment. During the measurement period, the Company may record adjustments to the provisional amounts recognized in the Company’s initial accounting for the acquisition. The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date).


	Estimated Fair Value
Current assets	$	3.1
Real property		20.7
Equipment		1.6
Goodwill		8.1
Current liabilities		(4.4	)
Long-term liabilities		(9.0	)

Total purchase price	$	20.1

(3)

MARKETABLE INVESTMENT SECURITIES

The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2015 and June 30, 2015 were as follows:


	Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses			Estimated fair value
At December 31, 2015:
Cash and cash equivalents:
Cash	$	114.0	$	—	$	—		$	114.0
Cash equivalents		20.7		—		—			20.7

Total cash and cash equivalents		134.7		—		—			134.7

Available-for-sale:
Corporate bonds and notes		45.5		—		(0.1	)		45.4
Municipal bonds		66.5		0.1		(0.1	)		66.5
Federal agency issues		38.9		—		—			38.9

Total	$	285.6	$	0.1	$	(0.2	)	$	285.5


	Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses			Estimated fair value
At June 30, 2015:
Cash and cash equivalents:
Cash	$	54.7	$	—	$	—		$	54.7
Cash equivalents		9.4		—		—			9.4

Total cash and cash equivalents		64.1		—		—			64.1

Available-for-sale:
Corporate bonds and notes		41.8		—		—			41.8
Municipal bonds		66.3		0.1		(0.1	)		66.3
Federal agency issues		13.2		—		—			13.2

Total	$	185.4	$	0.1	$	(0.1	)	$	185.4

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2015:


	Amortized cost		Estimated fair value
Cash	$	114.0	$	114.0
Cash equivalents		20.7		20.7
Available-for-sale:
Due within one year		84.6		84.6
Due after one year through five years		66.3		66.2
Due after five years		—		—

Total	$	285.6	$	285.5

(4)

PROPERTY, PLANT AND EQUIPMENT, NET


	December 31, 2015			June 30, 2015
Land	$	2.3		$	2.3
Buildings and improvements		17.3			18.2
Leasehold improvements		18.6			18.5
Equipment		101.0			99.1

		139.2			138.1
Less accumulated depreciation		(77.5	)		(70.9	)

Property, plant and equipment, net	$	61.7		$	67.2

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Depreciation expense

3.6

2.9

7.2

5.5

(5)

GOODWILL AND INTANGIBLE ASSETS

Goodwill

The Company has recorded goodwill of $177.0 from the acquisitions of Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $112.3 relates to the Company’s diagnostic segment and $64.7 relates to the other segment. The following summarizes changes to the goodwill balance for the six months ended December 31, 2015:


	Carrying amount
Beginning balance July 1, 2015	$	177.2
Acquisitions		—
Translation adjustments		(0.2	)

Ending balance December 31, 2015	$	177.0

Intangible Assets

Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:


At December 31, 2015:	Gross Carrying Amount		Accumulated Amortization			Net
Purchased licenses and technologies	$	199.1	$	(22.6	)	$	176.5
Customer relationships		4.7		(2.2	)		2.5
Trademarks		3.0		(0.5	)		2.5

Total amortized intangible assets		206.8		(25.3	)		181.5

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(25.3	)	$	186.3


At June 30, 2015:	Gross Carrying Amount		Accumulated Amortization			Net
Purchased licenses and technologies	$	199.1	$	(16.7	)	$	182.4
Customer relationships		4.7		(1.9	)		2.8
Trademarks		3.0		(0.4	)		2.6

Total amortized intangible assets		206.8		(19.0	)		187.8

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(19.0	)	$	192.6

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Amortization of intangible assets

3.2

3.1

6.3

6.5

(6)

COST BASIS INVESTMENT

As of December 31, 2015, the Company had a $5.0 investment in RainDance Technologies, Inc., which has been recorded under the cost method as an “Other Asset” on the Company’s condensed consolidated balance sheet. There were no events or circumstances that indicated that impairment exists; therefore, the Company recorded no impairment in the investment for the six months ended December 31, 2015.

(7)

ACCRUED LIABILITIES


	December 31, 2015		June 30, 2015
Employee compensation and benefits	$	34.4	$	33.8
Accrued taxes payable		4.7		3.8
Other		8.8		8.5

Total Accrued liabilities	$	47.9	$	46.1

(8)

OTHER LONG TERM LIABILITIES


	December 31, 2015		June 30, 2015
Pension obligation	$	4.8	$	4.9
Other		2.0		3.9

Total other long term liabilities	$	6.8	$	8.8

The Company has two non-contributory defined benefit pension plans for its current and former Clinic employees. The Company has closed participation in the plans to exclude those employees hired after 2002. As of December 31, 2015 the fair value of the plan assets were approximately $0.2 resulting in a net pension liability of $4.8.

(9)

PREFERRED AND COMMON STOCKHOLDER’S EQUITY

The Company is authorized to issue up to 5.0 shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at December 31, 2015.

The Company is authorized to issue up to 150.0 shares of common stock, par value $0.01 per share. There were 71.6 shares issued and outstanding at December 31, 2015.

Common shares issued and outstanding


	Six months ended December 31,
	2015			2014
Common stock issued and outstanding at July 1		68.9			73.5
Common stock issued upon exercise of options and employee stock plans		4.4			1.0
Repurchase and retirement of common stock		(1.7	)		(3.0	)

Common stock issued and outstanding at December 31		71.6			71.5

Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding.

The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Denominator:
Weighted-average shares outstanding used to compute basic EPS		70.5		72.5		69.6		72.6
Effect of dilutive shares		3.3		2.9		3.5		3.2

Weighted-average shares outstanding and dilutive securities used to compute diluted EPS		73.8		75.4		73.1		75.8

Certain outstanding options and restricted stock units (“RSUs”) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Anti-dilutive options and RSU’s excluded from EPS computation

—

0.9

—

Stock Repurchase Program

In February 2015, the Company’s Board of Directors authorized a seventh share repurchase program of $200.0 of the Company’s outstanding common stock. The Company plans to repurchase its common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by the Company’s management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of December 31, 2015, the Company has $91.6 remaining on its current share repurchase authorization.

The Company uses the par value method of accounting for its stock repurchases. As a result of the stock repurchases, the Company reduced common stock and additional paid-in capital and recorded charges to accumulated deficit. The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended December 31, 2015 and 2014 were as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Shares purchased and retired		0.6		1.7		1.7		3.0
Common stock and additional paid-in-capital reductions	$	5.4	$	14.8		14.9	$	25.0
Charges to retained earnings	$	20.0	$	43.6		48.5	$	79.0

(10)

INCOME TAXES

In order to determine the Company’s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.

Income tax expense for the three months ended December 31, 2015 was $14.7, or approximately 33% of pre-tax income, compared to $13.9, for the three months ended December 31, 2014, or approximately 37% of pre-tax income. Income tax expense for the six months ended December 31, 2015 was $31.6, or approximately 36% of pre-tax income, compared to $23.8, for the six months ended December 31, 2014, or approximately 37% of pre-tax income. Income tax expense for the three and six months ended December 31, 2015 is based on the Company’s estimated annual effective tax rate for the full fiscal year ending June 30, 2016, adjusted by discrete items recognized during the period. For the three and six months ended December 31, 2015, the Company’s recognized effective tax rate differs from the U.S. federal statutory rate of 35% primarily due to the effect of state income taxes, the reinstatement of the federal research tax credit, the sourcing of foreign losses and the benefits realized from the differences related to the earlier recognition of the tax effect of equity compensation expense from incentive stock options and the deduction realized when those options are disqualified upon exercise and sale.

The Company files U.S., foreign and state income tax returns in jurisdictions with various statutes of limitations. The Company’s New Jersey State income tax returns for the years ended June 30, 2007 through 2013 are currently under examination by the State of New Jersey Department of Treasury, Division of Taxation. Annual and interim tax provisions include amounts considered necessary to pay assessments that may result from examination of prior year tax returns; however, the amount ultimately paid upon resolution of issues may differ materially from the amount accrued. The Company’s U.S. federal tax return and other state tax returns are not currently under examination.

Pursuant to the guidelines of the recently issued Accounting Standards Update 2015-17 (“the Update”), all deferred tax assets and liabilities are to be classified as non-current. The effective date of the Update for public companies is for annual periods beginning after December 15, 2016 and later dates for all other entities. Early adoption is permitted. To comply with the guidance, the Company has elected to adopt this Update for the quarter ended December 31, 2015 and the annual period ending June 30, 2016. The guidance indicates that the Update may be applied either prospectively or retrospectively. The Company has chosen to apply the Update prospectively. Accordingly, no prior periods were adjusted. During the quarter ended December 31, 2015, approximately $13.5 of net current deferred tax assets were reclassified to non-current and netted against non-current deferred tax liabilities.

(11)

SHARE-BASED COMPENSATION

The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 3, 2015, the shareholders approved an amendment to the 2010 Plan to add 1.6 to the number of shares of common stock available for grant. At December 30, 2015, 2.3 shares of common stock were available for issuance. If an option or RSU issued or awarded under the 2010 Plan is cancelled or expires without the issuance of shares of common stock, the unissued or reacquired shares, which were subject to the option or RSU, shall again be available for issuance pursuant to the 2010 Plan. In addition, as of December 31, 2015, the Company may grant up to 2.5 additional shares of common stock under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire without the issuance of shares of common stock by the Company.

The number of shares, terms, and vesting period of awards under the 2010 Plan are determined by the Compensation Committee of the Board of Directors for each equity award. Stock options granted under the plan prior to December 5, 2012 generally vest ratably over four years and expire ten years from the grant date. Stock options granted after December 5, 2012 generally vest ratably over four years and expire eight years from the grant date. The exercise price of options granted is equivalent to the fair market value of the stock on the grant date. In September 2014, the Company began issuing restricted stock units (“RSUs”) which generally vest ratably over four years on the anniversary date of the grant in lieu of stock options to employees and directors. Beginning in fiscal 2016, RSUs issued will generally vest ratably over four years from the last day of the month in which the RSU award is granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional financial performance metrics are not met.

Stock Options

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2015 is as follows:


	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2015		12.5		$	23.49
Options granted		—		$	—
Less:
Options exercised		(4.0	)	$	21.38
Options canceled or expired		—		$	—

Options outstanding at December 31, 2015		8.5		$	24.50

Options exercisable at December 31, 2015		6.9		$	24.00

As of December 31, 2015, there was $10.8 of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.34 years.

Restricted Stock Units

A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2015 is as follows:


	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2015		1.0		$	37.63
RSUs granted		0.8		$	40.66
Less:
RSUs vested		(0.3	)	$	39.74
RSUs canceled		—		$	—

RSUs outstanding at December 31, 2015		1.5		$	38.80

As of December 31, 2015, there was $39.0 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.79 years.

This unrecognized compensation expense is equal to the fair value of RSUs expected to vest.

Employee Stock Purchase Plan

The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of December 31, 2015, approximately 0.7 shares of common stock have been issued under the 2012 Purchase Plan.

Share-Based Compensation Expense

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Cost of molecular diagnostic testing	$	0.3	$	0.2	$	0.5	$	0.4
Cost of pharmaceutical and clinical services		0.1		0.1		0.2		0.3
Research and development expense		1.2		1.3		2.8		2.0
Selling, general, and administrative expense		6.1		10.5		12.8		16.3

Total share-based compensation expense	$	7.7	$	12.1	$	16.3	$	19.0

(12)

FAIR VALUE MEASUREMENTS

The fair value of the Company’s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:


Level 1	—	quoted prices in active markets for identical assets and liabilities.

Level 2	—	observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.

Level 3	—	unobservable inputs.

All of the Company’s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application and corroborative information. The Company reviews, tests and validates this information. The following table sets forth the fair value of the financial assets that the Company re-measures on a regular basis:


	Level 1		Level 2		Level 3		Total
at December 31, 2015
Money market funds (a)	$	1.1	$	—	$	—	$	1.1
Corporate bonds and notes		—		59.6		—		59.6
Municipal bonds		—		66.5		—		66.5
Federal agency issues		—		44.3		—		44.3

Total	$	1.1	$	170.4	$	—	$	171.5

(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest


	Level 1		Level 2		Level 3		Total
at June 30, 2015
Money market funds (a)	$	2.4	$	—	$	—	$	2.4
Corporate bonds and notes		—		44.8		—		44.8
Municipal bonds		—		70.3		—		70.3
Federal agency issues		—		13.2		—		13.2

Total	$	2.4	$	128.3	$	—	$	130.7

(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

(13)

COMMITMENTS AND CONTINGENCIES

The Company is subject to various claims and legal proceedings covering matters that arise in the ordinary course of its business activities. As of December 31, 2015, the management of the Company believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s consolidated financial position, operating results, or cash flows.

(14)

EMPLOYEE DEFERRED SAVINGS PLAN

The Company has a deferred savings plan which qualifies under Section 401(k) of the Internal Revenue Code. Substantially all of the Company’s U.S. employees are covered by the plan. The Company makes matching contributions of 50% of each employee’s contribution with the employer’s contribution not to exceed 4% of the employee’s compensation. The Company’s recorded contributions to the plan as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Deferred savings plan Company contributions	$	1.2	$	1.1	$	2.7	$	2.5

(15)

SEGMENT AND RELATED INFORMATION

The Company’s business units have been aligned with how its Chief Operating Decision Maker (“CODM”) reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The prior periods presented have been restated to conform to the current presentation.

Segment revenue and operating income (loss) were as follows during the periods presented:


	Diagnostics		Other			Total
Three months ended December 31, 2015
Revenues	$	182.6	$	10.7		$	193.3
Depreciation and amortization		5.5		1.3			6.8
Segment operating income (loss)		64.6		(19.4	)		45.2
Three months ended December 31, 2014
Revenues	$	179.2	$	5.2		$	184.4
Depreciation and amortization		5.0		1.0			6.0
Segment operating income (loss)		59.0		(22.7	)		36.3
Six months ended December 31, 2015
Revenues	$	354.5	$	22.3		$	376.8
Depreciation and amortization		10.9		2.6			13.5
Segment operating income (loss)		127.0		(38.5	)		88.5
Six months ended December 31, 2014
Revenues	$	343.6	$	9.6		$	353.2
Depreciation and amortization		10.0		2.0			12.0
Segment operating income (loss)		104.1		(41.8	)		62.3


	Three months ended December 31,					Six months ended December 31,
	2015			2014		2015			2014
Total operating income for reportable segments	$	45.2		$	36.3	$	88.5		$	62.3
Unallocated amounts:
Interest income		0.1			0.1		0.2			0.1
Other		(0.3	)		1.5		(0.1	)		1.4

Income from operations before income taxes		45.0			37.9		88.6			63.8

Income tax provision		14.7			13.9		31.6			23.8

Net income	$	30.3		$	24.0	$	57.0		$	40.0

(16)

SUPPLEMENTAL CASH FLOW INFORMATION


	Six months ended December 31,
	2015			2014
Cash paid during the period for income taxes	$	28.5		$	12.8
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders’ equity	$	(0.2	)	$	(0.1	)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

General

We are a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives through pioneering molecular diagnostics. Through our proprietary technologies, we believe we are positioned to identify important disease genes, the proteins they produce, and the biological pathways in which they are involved to better understand the genetic basis of human disease and the role that genes and their related proteins may play in the disease process. We believe that identifying biomarkers (DNA, RNA and proteins) will enable us to develop novel molecular diagnostic tests that can provide important information to solve unmet medical needs. During the three months ended December 31, 2015, we reported total revenues of $193.3 million, net income of $30.3 million and diluted earnings per share of $0.41 that included income tax expense of $14.7 million. During the six months ended December 31, 2015, we reported total revenues of $376.8 million, net income of $57.0 million and diluted earnings per share of $0.78 that included income tax expense of $31.6 million.

On February 27, 2015, we completed the acquisition of Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG (the “Clinic”) which contributed approximately $5.0 million and $10.1 million of revenue in the current quarter and year to date respectively with no impact on diluted earnings per share. We believe the acquisition of the Clinic should facilitate our penetration into the German molecular diagnostic market. The Clinic will allow us to directly negotiate reimbursement with government and private insurance providers for our tests in the German market and collaborate with hospitals and physician groups.

Our business units have been aligned with how its Chief Operating Decision Maker (“CODM”) reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology.

Business Highlights

During the second quarter, we announced the issuance of a new patent pertaining to Vectra DA by the U.S. Patent and Trademark Office. This is the first issued patent covering the Vectra DA testing process.

In August, we received a favorable final local coverage determination for our Prolaris test from Noridian, the Medicare Administrative Contractor for the Company. The coverage determination became effective during this quarter, on October 15, 2015, and covers Prolaris for patients defined as low or very-low risk by the National Comprehensive Cancer Network guidelines.

We have developed two new companion diagnostics. The first is a tumor sequencing test panel that contains evaluating approximately 80 genes our pharmaceutical partners identified as clinically actionable in oncology and may augment our other companion products. The second is a proprietary immune pathway assay that can identify potential responders to immunotherapy. We have signed research collaborations with major undisclosed pharmaceutical partners utilizing both of these new products.

During the fiscal second quarter, we won a competitive tender for EndoPredict in France that is anticipated to begin generating revenue in calendar year 2016. Additionally, Helsana, the largest insurance provider in Switzerland, announced a favorable coverage decision for Prolaris.

Results of Operations for the Three Months Ended December 31, 2015 and 2014

Revenue


	Three months ended December 31,
(In millions)	2015		2014		Change
Revenue	$	193.3	$	184.4	$	8.9

The increase in revenue is primarily due to growth in pharmaceutical and clinical service revenues of $5.5 million, growth in hereditary cancer testing revenues of $1.6 million and growth in Prolaris revenues of $1.5 million. The increase in pharmaceutical and clinical service revenue was primarily driven by the acquisition of the Clinic. The increase in hereditary cancer revenue was driven by increased volume associated primarily with our myRisk hereditary cancer panel test. The increase in Prolaris revenue was driven by increased volumes and the initiation of Medicare coverage for a portion of the Medicare population effective October 15, 2015. Pricing and market share were relatively consistent with the prior year.

The following table presents additional detail regarding the composition of our total revenue for the three months ended December 31, 2015 and 2014:


	Three months ending December 31,				$			% of Total Revenue
(In millions)	2015		2014		Change			2015			2014
Molecular diagnostic revenues:
Hereditary Cancer Testing	$	166.6	$	165.0	$	1.6			86	%		89	%
VectraDA		11.3		10.8		0.5			6	%		6	%
Prolaris		1.9		0.4		1.5			1	%		0	%
Other		2.8		3.0		(0.2	)		1	%		2	%

Total molecular diagnostic revenue		182.6		179.2		3.4

Pharmaceutical and clinical service revenue		10.7		5.2		5.5			6	%		3	%

Total revenue	$	193.3	$	184.4	$	8.9			100	%		100	%

Cost of Sales


	Three months ended December 31,
(In millions)	2015			2014			Change
Cost of sales	$	40.6		$	37.9		$	2.7
Cost of sales as a % of sales		21.0	%		20.6	%

Cost of sales as a percentage of revenue increased from 20.6% to 21.0% during the three months ended December 31, 2015 compared to the same period in the prior year driven by the impact of the Clinic, which was acquired in February 2015. This increase was partially offset by improved efficiencies in the laboratory performing molecular diagnostic tests.

Research and Development Expenses


	Three months ended December 31,
(In millions)	2015			2014			Change
R&D expense	$	16.7		$	17.5		$	(0.8	)
R&D expense as a % of sales		8.6	%		9.5	%

Research and development expense for the three months ended December 31, 2015 decreased compared to the same period in the prior year driven by a reduction in the cost of formulating, improving, validating and creating alternative or modified processes relating to the myRisk production process and the timing of clinical studies. In general, costs associated with research and development can fluctuate dramatically due to the timing of clinical studies, the staging of products in the pipeline and other factors.

Selling, General and Administrative Expenses


	Three months ended December 31,
(In millions)	2015			2014			Change
SG&A expense	$	90.8		$	92.7		$	(1.9	)
SG&A expense as a % of sales		47.0	%		50.3	%

Selling, general and administrative expense decreased for the three months ended December 31, 2015 compared to the same period in the prior year due to a $4.8 million decrease in share-based compensation expense, of which $3.1 million related to the acceleration of vesting of certain options for our former Chief Financial Officer in the prior year period. This decrease was partially offset by a $1.7 million increase in costs relating to the Clinic acquisition and a $0.9 million increase in other general administrative expenses.

Other Income (Expense)


	Three months ended December 31,
(In millions)	2015			2014		Change
Other income (expense)	$	(0.2	)	$	1.6	$	(1.8	)

For the three months ended December 31, 2015 compared to the same period in the prior year, the decrease in other income was driven by the absence of foreign exchange gains on the funds held to acquire the Clinic in the prior year.

Income Tax Expense


	Three months ended December 31,
(In millions)	2015			2014			Change
Income tax expense	$	14.7		$	13.9		$	0.8
Effective tax rate		32.7	%		36.7	%

Our tax rate is the product of a U.S. federal effective rate of 35% and a blended state income tax rate of approximately 3%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period. The decrease in the effective rate for the three months ended December 31, 2015 as compared to the same period in prior year is due to a change in the tax treatment of net losses generated by our international operations for which an income tax benefit was recognized. Differences related to the recognition of the tax effect of equity compensation expense from the disqualification of incentive stock options also impacted the current and prior year effective tax rate.

Results of Operations for the Six Months Ended December 31, 2015 and 2014

Revenue


	Six months ended December 31,
(In millions)	2015		2014		Change
Revenue	$	376.8	$	353.2	$	23.6

The increase in revenue is primarily driven by growth in hereditary cancer testing revenues of $7.7 million and growth in pharmaceutical and clinical service revenues of $12.7 million. The increase in hereditary cancer revenue was driven by increased volume associated primarily with our myRisk hereditary cancer panel test and Medicare reimbursement associated with our Prolaris test. Pricing and market share were relatively consistent with the prior year. The increase in pharmaceutical and clinical service revenue was primarily due to the acquisition of the Clinic.

The following table presents additional detail regarding the composition of our total revenue for the six months ended December 31, 2015 and 2014:


	Six months ending December 31,				$		% of Total Revenue
(In millions)	2015		2014		Change		2015			2014
Molecular diagnostic revenues:
Hereditary Cancer Testing	$	323.2	$	315.5	$	7.7		86	%		89	%
VectraDA		22.7		21.4		1.3		6	%		6	%
Prolaris		2.6		0.8		1.8		1	%		0	%
Other		6.0		5.9		0.1		1	%		2	%

Total molecular diagnostic revenue		354.5		343.6		10.9

Pharmaceutical and clinical service revenue		22.3		9.6		12.7		6	%		3	%

Total revenue	$	376.8	$	353.2	$	23.6		100	%		100	%

Cost of Sales


	Six months ended December 31,
(In millions)	2015			2014			Change
Cost of sales	$	77.1		$	72.7		$	4.4
Cost of sales as a % of sales		20.5	%		20.6	%

Cost of sales as a percentage of revenue decreased from 20.6% to 20.5% during the six months ended December 31, 2015 compared to the same period in the prior year driven by improved efficiencies in the laboratory performing molecular diagnostic tests. This was partially offset by the impact of the Clinic, which was acquired in February 2015.

Research and Development Expenses


	Six months ended December 31,
(In millions)	2015			2014			Change
R&D expense	$	33.9		$	40.1		$	(6.2	)
R&D expense as a % of sales		9.0	%		11.4	%

Research and development expense for the six months ended December 31, 2015 decreased compared to the same period in the prior year driven by a reduction in the cost of formulating, improving, validating and creating alternative or modified processes relating to the myRisk production process and the timing of clinical studies. In general, costs associated with research and development can fluctuate dramatically due to the timing of clinical studies, the staging of products in the pipeline and other factors.

Selling, General and Administrative Expenses


	Six months ended December 31,
(In millions)	2015			2014			Change
SG&A expense	$	177.3		$	178.1		$	(0.8	)
SG&A expense as a % of sales		47.1	%		50.4	%

Selling, general and administrative expense decreased for the six months ended December 31, 2015 compared to the same period in the prior year due to $4.1 million reduction in share-based compensation expense, of which $3.1 million related to the acceleration of vesting of certain options for our former Chief Financial Officer in the prior year period. This decrease was largely offset by a $3.8 million increase in costs relating to the Clinic acquisition.

Other Income (Expense)


	Six months ended December 31,
(In millions)	2015		2014		Change
Other income	$	0.1	$	1.5	$	(1.4	)

For the six months ended December 31, 2015 compared to the same period in the prior year, the decrease in other income was driven by the absence of foreign exchange gains on funds held to acquire the Clinic in the prior year.

Income Tax Expense


	Six months ended December 31,
(In millions)	2015			2014			Change
Income tax expense	$	31.6		$	23.8		$	7.8
Effective tax rate		35.7	%		37.3	%

Our tax rate is the product of a U.S. federal effective rate of 35% and a blended state income tax rate of approximately 3%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period. The decrease in the effective rate for the six months ended December 31, 2015 as compared to the same period in the prior year is due to a change in the tax treatment of net losses generated by our international operations for which an income tax benefit was recognized. Differences related to the recognition of the tax effect of equity compensation expense from the disqualification of incentive stock options also impacted the current and prior year effective tax rate.

Liquidity and Capital Resources

We believe that with our existing capital resources and expected net cash to be generated from sales, that we will have adequate funds to maintain our current and planned operations for the foreseeable future, although no assurance can be given that changes will not occur that would consume available capital resources more quickly than we currently expect and that we may need or want to raise capital.

Our capital deployment strategy focuses on use of resources in three key areas: research and development, acquisitions and the repurchase of our common stock. We believe that research and development provides the best return on invested capital. We also allocate capital for acquisitions that support our business strategy and share repurchases based on business and market conditions.

The following table represents the balances of cash, cash equivalents and marketable investment securities:


(In millions)	December 31, 2015		June 30, 2015		Change
Cash and cash equivalents	$	134.7	$	64.1	$	70.6
Marketable investment securities		84.6		80.7		3.9
Long-term marketable investment securities		66.2		40.6		25.6

Cash, cash equivalents and marketable investment securities	$	285.5	$	185.4	$	100.1

For the six months ended December 31, 2015, the increase in cash, cash equivalents and marketable investment securities was primarily driven by the $84.9 million in net proceeds from common stock issued under share-based compensation plans and $65.8 million in cash provided by operating activities. These increases were partially offset by $62.9 million used for the repurchase and retirement of common stock.

The following table represents the condensed consolidated cash flow statement:


	Six months ended December 31,
(In millions)	2015			2014			Change
Cash flows from operating activities	$	65.8			59.6		$	6.2
Cash flows from investing activities		(31.5	)		18.8			(50.3	)
Cash flows from financing activities		38.1			(81.1	)		119.2
Effect of foreign exchange rates on cash and cash equivalents		(1.8	)		(2.4	)		0.6

Net increase in cash and cash equivalents		70.6			(5.1	)		75.7
Cash and cash equivalents at the beginning of the year		64.1			64.8			(0.7	)

Cash and cash equivalents at the end of the period	$	134.7		$	59.7		$	75.0

Cash Flows from Operating Activities

The increase in cash flows from operating activities for the six months ended December 31, 2015, compared to the same period in the prior year, was due to the $17.0 million increase in net income and $14.2 million increase in non-cash charges included in net income partially offset by a $25.0 million decrease due to changes in assets and liabilities.

Cash Flows from Investing Activities

For the six months ended December 31, 2015, compared to the same period in the prior year, the decrease in cash flows from investing activities was primarily related to the $78.1 million increase in purchases of marketable investment securities partially offset by the reduction of $21.6 in restricted cash which, in fiscal 2015, was used for the acquisition of the Clinic.

Cash Flows from Financing Activities

For the six months ended December 31, 2015, compared to the same period in the prior year, the increase in cash flows from financing activities was driven primarily by the $64.7 million increase in net proceeds from stock issued under share-based compensation plans and the $41.0 million reduction in cash spent for the repurchase and retirement of common stock.

Effects of Inflation

We do not believe that inflation has had a material impact on our business, sales, or operating results during the periods presented.

Share Repurchase Program

In February 2015, our Board of Directors authorized a seventh share repurchase program of $200 million of our outstanding common stock. We plan to repurchase our common stock from time to time or on an accelerated basis through open market transactions or privately negotiated transactions as determined by our management. The amount and timing of stock repurchases under the program will depend on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of December 31, 2015, we have $91.6 million remaining on our current share repurchase authorization. See also “Part II, Item 2. Unregistered Sales of Equity Securities and Use of Proceeds – Issuer Purchases of Equity Securities.”

Critical Accounting Policies

Critical accounting policies are those policies which are both important to the presentation of a company’s financial condition and results and require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. No significant changes to our accounting policies took place during the period. For a further discussion of our critical accounting policies, see our Annual Report on Form 10-K for the fiscal year ended June 30, 2015.

Certain Factors That May Affect Future Results of Operations

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

Words such as “may,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes,” “seek,” “could,” continue,” “likely,” “will,” “strategy, “goal” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of a healthcare clinic in Germany; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for the fiscal year ended June 30, 2015, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no material changes in our market risk during the six months ended December 31, 2015 compared to the disclosures in Part II, Item 7A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2015, which is incorporated by reference herein.

Item 4. Controls and Procedures

(a)

Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b)

Changes in Internal Controls. There were no changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - Other Information

Item 1. Legal Proceedings

We are presently not a party to any legal proceedings that we believe will have a material impact on our business, financial position or results of operations.

Item 1A. Risk Factors

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

Issuer Purchases of Equity Securities

In February 2015, we announced that our board of directors had authorized us to repurchase an additional $200.0 million of our outstanding common stock increasing the cumulative share repurchase authorization since we first authorized the program in May 2010 to $1.2 billion. In connection with our most recent stock repurchase authorization, we have been authorized to complete the repurchase through open market transactions or through an accelerated share repurchase program, in each case to be executed at management’s discretion based on business and market conditions, stock price, trading restrictions, acquisition activity and other factors. As of the date of this report, we have not entered into an accelerated share repurchase agreement under our most recent stock repurchase program. The repurchase program may be suspended or discontinued at any time without prior notice. The transactions effectuated to date occurred in open market purchases.

During the three months ended December 31, 2015 we acquired the following shares of common stock under our stock repurchase program:


Period	(a) Total Number of Shares Purchased	(b) Average Price Paid per Share		(c) Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs		(d) Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs
October 1, 2015 to October 31, 2015	0.2	$	38.62		0.2		110.4
November 1, 2015 to November 30, 2015	0.2	$	43.83		0.2		102.5
December 1, 2015 to December 31, 2015	0.2	$	43.37		0.2		91.6

Total	0.6				0.6		91.6

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

None.

Item 5. Other Information.

None.

Item 6. Exhibits.

10.1

Non-Employee Director Compensation Policy.+

31.1

Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

31.2

Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.

32.1

Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).

101

The following materials from Myriad Genetics, Inc.’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2015, formatted in XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets, (ii) the unaudited Condensed Consolidated Statements of Operations (iii) the unaudited Consolidated Statement of Comprehensive Income, (iv) the unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements.

(+)	Management contract or compensatory plan arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	MYRIAD GENETICS, INC.

Date: February 3, 2016	By:	/s/ Mark C. Capone
		Mark C. Capone
		President and Chief Executive Officer
		(Principal executive officer)

Date: February 3, 2016	By:	/s/ R. Bryan Riggsbee
		R. Bryan Riggsbee
		Executive Vice President, Chief Financial Officer
		(Principal financial and chief accounting officer)

EX-10.1 2 d105198dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

MYRIAD GENETICS, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

(Effective December 2, 2015)

The following is a description of the standard compensation arrangements under which our non-employee directors are compensated for their service as directors, including as members of the various committees of our Board.


Annual Retainer (all members)		$60,000

Chairman of the Board		$100,000 additional retainer

Committee Chair Compensation
Audit Committee		$28,000 additional retainer
Compensation Committee		$20,000 additional retainer
Nominating and Governance Committee		$15,000 additional retainer

Committee Member Compensation
Audit Committee (1)		$13,500 additional retainer
Compensation Committee (1)		$10,000 additional retainer
Nominating and Governance Committee(1)		$7,500 additional retainer
Strategic Committee		$5,000 additional retainer

(1)	Other than each Committee Chair

Attendance

Board Meetings: In addition to the annual retainer amounts, we pay each non-employee director a per-meeting cash fee of $2,000 for attendance at Board meetings in excess of five in-person meetings and four telephonic meetings per fiscal year.

Committee Meetings other than Strategic Committee: We pay each non-employee director a per-meeting cash fee of $2,000 for attendance at committee meetings in excess of four meetings (per each committee), whether in person or telephonic, per fiscal year.

Strategic Committee: No per meeting fees.

All directors are also reimbursed for their out-of pocket expenses incurred in attending meetings.

Stock Option, Restricted and Unrestricted Stock Grants and Other-Stock-Based Awards

Under our 2010 Employee, Director and Consultant Equity Incentive Plan (the “2010 Plan”), our non-employee directors may be awarded stock options, restricted and unrestricted stock grants and/or other stock-based awards. As recommended and determined by our Compensation Committee, and approved by our Board of Directors, on each date of our annual meeting of stockholders, the Company shall grant to each non-employee director, other than new non-employee directors appointed within six months of the annual meeting, a restricted stock unit award for 7,500 shares of common stock of the Company. In addition, it is our policy to grant a restricted stock unit award for 7,500 shares of common stock to each new non-employee director upon initial appointment to the Board.

Options and restricted stock units granted to our non-employee directors vest in full upon the earlier of (i) one full year of service on the Board following date of grant or (ii) the date of the next annual meeting of stockholders. Options granted to our non-employee directors are exercisable after the termination of the director’s service on the Board to the extent exercisable on the date of such termination for the remainder of the life of the option. All options or restricted stock units granted to our non-employee directors will become fully exercisable upon a change of control of Myriad or upon their death as provided for under the forms of award agreement for directors under our 2010 Plan.

EX-31.1 3 d105198dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, Mark C. Capone, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 3, 2016


By:		/s/ Mark C. Capone
		Mark C. Capone
		President and Chief Executive Officer

EX-31.2 4 d105198dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

SARBANES-OXLEY SECTION 302(a) CERTIFICATION

I, R. Bryan Riggsbee, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: February 3, 2016


By:		/s/ R. Bryan Riggsbee
		R. Bryan Riggsbee
		Executive Vice President, Chief Financial Officer
		(Principal financial and chief accounting officer)

EX-32.1 5 d105198dex321.htm EX-32.1 EX-32.1

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended December 31, 2015 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: February 3, 2016		Date: February 3, 2016

By:	/s/ Mark C. Capone	By:	/s/ R. Bryan Riggsbee
Mark C. Capone		R. Bryan Riggsbee
President and Chief Executive Officer		Executive Vice President, Chief Financial Officer

EX-101.INS 6 mygn-20151231.xml XBRL INSTANCE DOCUMENT

4400000

9000000

3100000

8100000

20700000

20100000

1600000

200000000

1600000

2300000

73500000

64800000

12500000

68900000

23.49

68900000

68700000

33800000

70900000

200000

46100000

104100000

3800000

19000000

700000

745400000

7600000

26400000

4900000

8800000

3900000

1500000

-7000000

100000

8500000

-77000000

662100000

766200000

21100000

18200000

100000

192600000

67200000

283600000

2300000

177200000

80700000

13500000

1900000

206800000

187800000

18500000

4800000

64100000

766200000

130700000

211600000

185400000

85800000

138100000

5000000

40600000

25100000

99100000

12500000 185400000

1000000

37.63

70300000

2400000

13200000

44800000

2400000

128300000

400000

3000000

2600000

1900000

4700000

2800000

16700000

199100000

182400000

4800000

64100000

100000

66300000

100000

66300000

9400000

13200000

41800000

54700000

71500000

59700000

8500000

0.01

24.00

150000000

71600000

5000000

6900000

24.50

71600000

0.01

65900000

91600000

34400000

77500000

300000

47900000

100900000

4700000

25300000

700000

847800000

6200000

27900000

4800000

6800000

2000000

1500000

-9100000

100000

8800000

-68600000

770800000

871700000

16500000

17300000

200000

186300000

200000

61700000

375500000

2300000

66300000

177000000

84600000

5100000

84600000

206800000

181500000

18600000

4800000

134700000

10800000

871700000

171500000

13500000

66200000

211600000

285600000

84300000

139200000

28000000

5000000

66200000

29100000

101000000

2 9700000 285500000

1500000

38.80

39000000

2000000

66500000

1100000

44300000

59600000

64700000

112300000

1100000

170400000

5000000

500000

3000000

2500000

2200000

4700000

2500000

22600000

199100000

176500000

4800000

134700000

100000

66500000

100000

66500000

20700000

38900000

45400000

100000

45500000

114000000

71252152

20100000

3200000

1000000

72600000

0.37

3000000

59600000

0.55

1100000

75800000

0.53

2600000

1600000

37300000

343600000

1400000

62300000

-3700000

63800000

353200000

13900000

21600000

100000

-1900000

500000

1500000

17500000

40000000

9600000

-300000

22600000

-2400000

103900000

-8000000

12800000

800000

12000000

5500000

-81100000

6500000

-2400000

67800000

23800000

20200000

14000000

700000

290900000

-5100000

2500000

-100000

-6200000

2600000

19000000

178100000

-15200000

80500000

18800000

40100000

79000000 25000000 4900000

-41800000

9600000

2000000

104100000

343600000

10000000

3000000

2000000

16300000

400000

300000

10-Q MYGN

<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr> <td width="4%" valign="top" align="left">(4)</td> <td align="left" valign="top">PROPERTY, PLANT AND EQUIPMENT, NET</td> </tr> </table>   <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Land </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.3</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Buildings and improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.2</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.5</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101.0</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">99.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">139.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">138.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(77.5</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(70.9</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Property, plant and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">61.7</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">67.2</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.5</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> </table> </div>

<div> The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2015 and June 30, 2015 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At December 31, 2015: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">134.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">134.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Available-for-sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds and notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Municipal bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Federal agency issues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At June 30, 2015: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Available-for-sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds and notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Municipal bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Federal agency issues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0000899923 2015-12-31

3500000

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(3)</td> <td valign="top" align="left">MARKETABLE INVESTMENT SECURITIES</td> </tr> </table> The Company has classified its marketable investment securities as available-for-sale securities. These securities are carried at estimated fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated other comprehensive loss in stockholders’ equity until realized. Gains and losses on investment security transactions are reported on the specific-identification method. Dividend and interest income are recognized when earned. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2015 and June 30, 2015 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="66%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At December 31, 2015: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">134.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">134.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Available-for-sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds and notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Municipal bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Federal agency issues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">38.9</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 1pt"> <td height="16"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> <td height="16" colspan="4"></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding gains</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross unrealized holding losses</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> At June 30, 2015: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash and cash equivalents: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">54.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">9.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total cash and cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Available-for-sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds and notes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">41.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Municipal bonds </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Federal agency issues </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">185.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Available-for-sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Due within one year </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Due after one year through five years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Due after five years </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

Large Accelerated Filer

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(11)</td> <td valign="top" align="left">SHARE-BASED COMPENSATION</td> </tr> </table> The Company maintains a share-based compensation plan, the 2010 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2010 Plan”), that has been approved by the Company’s shareholders. The 2010 Plan allows the Company, under the direction of the Compensation Committee of the Board of Directors, to make grants of stock options, restricted and unrestricted stock awards and other stock-based awards to employees, consultants and directors. On December 3, 2015, the shareholders approved an amendment to the 2010 Plan to add 1.6 to the number of shares of common stock available for grant. At December 30, 2015, 2.3 shares of common stock were available for issuance. If an option or RSU issued or awarded under the 2010 Plan is cancelled or expires without the issuance of shares of common stock, the unissued or reacquired shares, which were subject to the option or RSU, shall again be available for issuance pursuant to the 2010 Plan. In addition, as of December 31, 2015, the Company may grant up to 2.5 additional shares of common stock under the 2010 Plan if options previously granted under the Company’s terminated 2003 Employee, Director and Consultant Option Plan are cancelled or expire without the issuance of shares of common stock by the Company. The number of shares, terms, and vesting period of awards under the 2010 Plan are determined by the Compensation Committee of the Board of Directors for each equity award. Stock options granted under the plan prior to December 5, 2012 generally vest ratably over four years and expire ten years from the grant date. Stock options granted after December 5, 2012 generally vest ratably over four years and expire eight years from the grant date. The exercise price of options granted is equivalent to the fair market value of the stock on the grant date. In September 2014, the Company began issuing restricted stock units (“RSUs”) which generally vest ratably over four years on the anniversary date of the grant in lieu of stock options to employees and directors. Beginning in fiscal 2016, RSUs issued will generally vest ratably over four years from the last day of the month in which the RSU award is granted. The number of RSUs awarded to certain executive officers may be reduced if certain additional financial performance metrics are not met.   Stock Options A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2015 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted average exercise price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.38</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options canceled or expired </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options outstanding at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.50</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options exercisable at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.00</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> As of December 31, 2015, there was $10.8 of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.34 years. Restricted Stock Units A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2015 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted average grant date fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> RSUs outstanding at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37.63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> RSUs granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40.66</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> RSUs vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.74</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> RSUs canceled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> RSUs outstanding at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38.80</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> As of December 31, 2015, there was $39.0 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.79 years. This unrecognized compensation expense is equal to the fair value of RSUs expected to vest. Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was approved by shareholders in 2012 (the “2012 Purchase Plan”), under which 2.0 shares of common stock have been authorized. Shares are issued under the 2012 Purchase Plan twice yearly at the end of each offering period. As of December 31, 2015, approximately 0.7 shares of common stock have been issued under the 2012 Purchase Plan.   Share-Based Compensation Expense Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cost of molecular diagnostic testing </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cost of pharmaceutical and clinical services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Selling, general, and administrative expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(15)</td> <td valign="top" align="left">SEGMENT AND RELATED INFORMATION</td> </tr> </table> The Company’s business units have been aligned with how its Chief Operating Decision Maker (“CODM”) reviews performance and makes decisions in managing the Company. The business units have been aggregated into two reportable segments: (i) diagnostics and (ii) other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to ensure optimal treatment, or assess a patient’s risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and includes corporate services such as finance, human resources, legal and information technology. The prior periods presented have been restated to conform to the current presentation. Segment revenue and operating income (loss) were as follows during the periods presented:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">182.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">193.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">179.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">184.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">354.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">376.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(38.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">343.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">353.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total operating income for reportable segments </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">88.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">62.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Unallocated amounts: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Income from operations before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Income tax provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

4400000

--06-30

<div> The following summarizes changes to the goodwill balance for the six months ended December 31, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Carrying amount</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance July 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Acquisitions </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Translation adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.2</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

69600000

0.36

<div> The following table sets forth the fair value of the financial assets that the Company re-measures on a regular basis:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market funds (a) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds and notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Municipal bonds </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Federal agency issues </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">170.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">171.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Money market funds are primarily comprised of exchange traded funds and accrued interest</td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="71%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 1</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 2</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Level 3</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Money market funds (a) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Corporate bonds and notes </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">44.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Municipal bonds </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Federal agency issues </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">128.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">130.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(a)</td> <td valign="top" align="left">Money market funds are primarily comprised of exchange traded funds and accrued interest</td> </tr> </table> </div>

<div> <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"> <tr> <td width="76%"></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="8%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">December 31, 2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">June 30, 2015</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Land </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.3</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Buildings and improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">17.3</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.2</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Leasehold improvements </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.6</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">18.5</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">101.0</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">99.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"></td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">139.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">138.1</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Less accumulated depreciation </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(77.5</td> <td nowrap="nowrap" valign="bottom">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(70.9</td> <td nowrap="nowrap" valign="bottom">) </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Property, plant and equipment, net </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">61.7</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">67.2</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> <tr style="font-size:1px;"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table cellspacing="0" cellpadding="0" width="92%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" align="center"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"> Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="font-family:Times New Roman; font-size:8pt"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000">2014</td> <td valign="bottom"> </td> </tr> <tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"> <td valign="top"> Depreciation expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.6</td> <td nowrap="nowrap" valign="bottom"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.9</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">7.2</td> <td nowrap="nowrap" valign="bottom">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.5</td> <td nowrap="nowrap" valign="bottom">  </td> </tr> </table> </div>

1700000

65800000

<div> A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2015 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="81%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted average exercise price</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options outstanding at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">23.49</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options granted </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options exercised </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">21.38</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options canceled or expired </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Options outstanding at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.50</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Options exercisable at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.00</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

<div> Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="78%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Amortized cost</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">114.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cash equivalents </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Available-for-sale: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Due within one year </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">84.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Due after one year through five years </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">66.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Due after five years </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">285.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

false

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left">(5)</td> <td valign="top" align="left">GOODWILL AND INTANGIBLE ASSETS</td> </tr> </table> Goodwill The Company has recorded goodwill of $177.0 from the acquisitions of Privatklinik Dr. Robert Schindlbeck GmbH & Co. KG that was completed on February 27, 2015, Crescendo Bioscience, Inc. that was completed on February 28, 2014 and Rules-Based Medicine, Inc. that was completed on May 31, 2011. Of this goodwill, $112.3 relates to the Company’s diagnostic segment and $64.7 relates to the other segment. The following summarizes changes to the goodwill balance for the six months ended December 31, 2015:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="89%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Carrying amount</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Beginning balance July 1, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Acquisitions </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Translation adjustments </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.2</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Ending balance December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">177.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> Intangible Assets Intangible assets primarily consist of amortizable assets of purchased licenses and technologies, customer relationships, and trade names as well as non-amortizable intangible assets of in-process technologies and research and development. The following summarizes the amounts reported as intangible assets:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">At December 31, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Purchased licenses and technologies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">199.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">176.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trademarks </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total amortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">206.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(25.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">181.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> In-process research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total unamortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">211.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(25.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">186.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">At June 30, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Purchased licenses and technologies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">199.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">182.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trademarks </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total amortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">206.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">187.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> In-process research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total unamortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">211.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(19.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">192.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> The Company recorded amortization expense during the respective periods for these intangible assets as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Amortization of intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

21.38

4000000

<div> The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Denominator: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted-average shares outstanding used to compute basic EPS </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">70.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72.5</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">69.6</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">72.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Effect of dilutive shares </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Weighted-average shares outstanding and dilutive securities used to compute diluted EPS </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75.4</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">75.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

MYRIAD GENETICS INC

0.82

<div> The Company recorded amortization expense during the respective periods for these intangible assets as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="72%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Amortization of intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.1</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.3</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

2016

<div> These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Anti-dilutive options and RSU’s excluded from EPS computation </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.9</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

1500000

<div> A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2015 is as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="80%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Number of shares</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Weighted average grant date fair value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> RSUs outstanding at June 30, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">37.63</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> RSUs granted </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40.66</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Less: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> RSUs vested </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">39.74</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> RSUs canceled </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap">$</td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> RSUs outstanding at December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">38.80</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> </table> </div>

73100000

<div> Common shares issued and outstanding   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="86%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Common stock issued and outstanding at July 1 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">68.9</td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">73.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock issued upon exercise of options and employee stock plans </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Repurchase and retirement of common stock </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.7</td> <td valign="bottom" nowrap="nowrap">)</td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(3.0</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock issued and outstanding at December 31 </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">71.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

0.78

<div> Segment revenue and operating income (loss) were as follows during the periods presented:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="74%"></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="5%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Diagnostics</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Other</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Total</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">182.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">10.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">193.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">64.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Three months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">179.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">184.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">5.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">59.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(22.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">36.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2015 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">354.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">22.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">376.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">127.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(38.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Six months ended December 31, 2014 </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Revenues </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">343.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">9.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">353.2</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Depreciation and amortization </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Segment operating income (loss) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">104.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(41.8</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">62.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total operating income for reportable segments </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">45.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">36.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">88.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">62.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Unallocated amounts: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Interest income </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Other </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Income from operations before income taxes </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">45.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">37.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">88.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">63.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Income tax provision </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">13.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">31.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">23.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Net income </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">30.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">24.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">57.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">40.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"> <tr> <td width="84%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cash paid during the period for income taxes </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">28.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Non-cash investing and financing activities: </td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom"></td> <td valign="bottom"></td> <td valign="bottom"></td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Fair value adjustment on marketable investment securities recorded to stockholders’ equity </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(0.1</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> </table> </div>

0.35

<div> Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="73%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Cost of molecular diagnostic testing </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">0.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Cost of pharmaceutical and clinical services </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Research and development expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Selling, general, and administrative expense </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">6.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">10.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">12.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">16.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total share-based compensation expense </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">7.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">12.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">16.3</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">19.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div>

16100000

5300000

54900000

354500000

-100000

88500000

4100000

88600000

400000

376800000

11100000

200000

-29800000

100000

2100000

57000000

22300000

-100000

100700000

-2000000

62900000

28000000

28500000

-2800000

13500000

7200000

38100000

6300000

-1800000

65000000

31600000

84900000

14500000

288300000

70600000

2700000

-200000

-4100000

16100000

16300000

177300000

-500000

71300000

-200000

-31500000

33900000

0.50 <div> The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date).   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"> <tr> <td width="83%"></td> <td valign="bottom" width="13%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Estimated Fair Value</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Current assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">3.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Real property </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">20.7</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Equipment </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Goodwill </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">8.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Current liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(4.4</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Long-term liabilities </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(9.0</td> <td valign="bottom" nowrap="nowrap">) </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total purchase price </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.1</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> <div> The following summarizes the amounts reported as intangible assets:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">At December 31, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Purchased licenses and technologies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">199.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(22.6</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">176.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(2.2</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trademarks </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.5</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total amortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">206.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(25.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">181.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> In-process research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total unamortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">211.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(25.3</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">186.3</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="84%" align="center" border="0"> <tr> <td width="70%"></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="6%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom" nowrap="nowrap">At June 30, 2015:</td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Gross Carrying Amount</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Accumulated Amortization</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">Net</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Purchased licenses and technologies </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">199.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(16.7</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">182.4</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Customer relationships </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(1.9</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Trademarks </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(0.4</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">2.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total amortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">206.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">(19.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">187.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> In-process research and development </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Total unamortized intangible assets </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom" nowrap="nowrap"> </td> <td valign="bottom" nowrap="nowrap" align="right"> —  </td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">4.8</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Total intangible assets </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">211.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">(19.0</td> <td valign="bottom" nowrap="nowrap">) </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">192.6</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 1px"> <td valign="bottom"></td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> <td valign="bottom">  </td> <td valign="bottom">   </td> <td valign="bottom">   </td> <td> </td> </tr> </table> </div> 48500000 14900000 <div> The Company’s recorded contributions to the plan as follows:   <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="4%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Deferred savings plan Company contributions </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.2</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">1.1</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">2.5</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div> 12100000 0.04 <div> The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended December 31, 2015 and 2014 were as follows:   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"> <tr> <td width="76%"></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> <td valign="bottom" width="3%"></td> <td></td> <td></td> <td></td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Three months ended December 31,</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">Six months ended December 31,</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2015</td> <td valign="bottom"> </td> <td valign="bottom">  </td> <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">2014</td> <td valign="bottom"> </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Shares purchased and retired </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">0.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">1.7</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">3.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"> <td valign="top"> Common stock and additional paid-in-capital reductions </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">5.4</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">14.8</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">14.9</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">25.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"> <td valign="top"> Charges to retained earnings </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">20.0</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">43.6</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom"> </td> <td valign="bottom" align="right">48.5</td> <td valign="bottom" nowrap="nowrap">  </td> <td valign="bottom">  </td> <td valign="bottom">$</td> <td valign="bottom" align="right">79.0</td> <td valign="bottom" nowrap="nowrap">  </td> </tr> </table> </div>

P1Y4M2D

P4Y

P10Y

P8Y

P2Y9M15D

40.66

300000

800000

39.74

700000

2500000

-38500000

22300000

2600000

127000000

354500000

10900000

1700000

2800000

12800000

500000

200000

P15Y

P4Y

2900000

900000

72500000

0.37

0.33

75400000

0.32

22200000

179200000

1500000

36300000

37900000

184400000

100000

1600000

24000000

5200000

-100000

-1700000

6000000

2900000

3100000

35100000

13900000

148100000

1100000

12100000

92700000

17500000

43600000 14800000 2800000

-22700000

5200000

1000000

59000000

179200000

5000000

1700000

1300000

10500000

200000

100000

3300000

70500000

0.33

0.43

73800000

0.41

0.35

28300000

182600000

-300000

45200000

45000000

193300000

100000

-200000

30300000

10700000

-200000

-1800000

6800000

3600000

3200000

34100000

14700000

148100000

1200000

7700000

90800000

16700000

20000000 5400000 6500000

-19400000

10700000

1300000

64600000

182600000

5500000

600000

1200000

6100000

300000

100000

0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2015-10-01 2015-12-31 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2015-10-01 2015-12-31 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-10-01 2015-12-31 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2015-10-01 2015-12-31 0000899923 us-gaap:CommonStockMember 2015-10-01 2015-12-31 0000899923 mygn:DiagnosticsMember 2015-10-01 2015-12-31 0000899923 us-gaap:AllOtherSegmentsMember 2015-10-01 2015-12-31 0000899923 2015-10-01 2015-12-31 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2014-10-01 2014-12-31 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2014-10-01 2014-12-31 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-10-01 2014-12-31 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2014-10-01 2014-12-31 0000899923 us-gaap:CommonStockMember 2014-10-01 2014-12-31 0000899923 mygn:DiagnosticsMember 2014-10-01 2014-12-31 0000899923 us-gaap:AllOtherSegmentsMember 2014-10-01 2014-12-31 0000899923 2014-10-01 2014-12-31 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2014-09-01 2014-09-30 0000899923 mygn:GermanClinicMember 2015-07-01 2015-12-31 0000899923 mygn:RainDanceTechnologiesMember 2015-07-01 2015-12-31 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2015-07-01 2015-12-31 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2015-07-01 2015-12-31 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2015-07-01 2015-12-31 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2015-07-01 2015-12-31 0000899923 us-gaap:CommonStockMember 2015-07-01 2015-12-31 0000899923 mygn:DiagnosticsMember 2015-07-01 2015-12-31 0000899923 us-gaap:AllOtherSegmentsMember 2015-07-01 2015-12-31 0000899923 mygn:EmployeeDirectorAndConsultantEquityIncentivePlanMemberus-gaap:MaximumMember 2015-07-01 2015-12-31 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2015-07-01 2015-12-31 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2015-07-01 2015-12-31 0000899923 mygn:OptionsGrantedAfterDecemberFiveTwentyTwelveMemberus-gaap:EmployeeStockOptionMember 2015-07-01 2015-12-31 0000899923 mygn:OptionsGrantedPriorToDecemberFiveTwentyTwelveMemberus-gaap:EmployeeStockOptionMember 2015-07-01 2015-12-31 0000899923 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-12-31 0000899923 2015-07-01 2015-12-31 0000899923 mygn:CostOfPharmaceuticalAndClinicalServicesMember 2014-07-01 2014-12-31 0000899923 mygn:CostOfMolecularDiagnosticTestingMember 2014-07-01 2014-12-31 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2014-07-01 2014-12-31 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2014-07-01 2014-12-31 0000899923 us-gaap:CommonStockMember 2014-07-01 2014-12-31 0000899923 mygn:DiagnosticsMember 2014-07-01 2014-12-31 0000899923 us-gaap:AllOtherSegmentsMember 2014-07-01 2014-12-31 0000899923 2014-07-01 2014-12-31 0000899923 mygn:GermanClinicMember 2015-02-27 2015-02-27 0000899923 2016-01-29 0000899923 us-gaap:CashMember 2015-12-31 0000899923 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000899923 us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000899923 us-gaap:CashEquivalentsMember 2015-12-31 0000899923 us-gaap:MunicipalBondsMember 2015-12-31 0000899923 us-gaap:CashAndCashEquivalentsMember 2015-12-31 0000899923 mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember 2015-12-31 0000899923 mygn:PurchasedLicensesAndTechnologiesMember 2015-12-31 0000899923 us-gaap:CustomerRelationshipsMember 2015-12-31 0000899923 us-gaap:TrademarksMember 2015-12-31 0000899923 mygn:RainDanceTechnologiesMember 2015-12-31 0000899923 us-gaap:FairValueInputsLevel2Member 2015-12-31 0000899923 us-gaap:FairValueInputsLevel1Member 2015-12-31 0000899923 mygn:DiagnosticsMember 2015-12-31 0000899923 us-gaap:AllOtherSegmentsMember 2015-12-31 0000899923 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2015-12-31 0000899923 us-gaap:CorporateDebtSecuritiesMember 2015-12-31 0000899923 us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member 2015-12-31 0000899923 us-gaap:USTreasuryAndGovernmentMember 2015-12-31 0000899923 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2015-12-31 0000899923 us-gaap:MoneyMarketFundsMember 2015-12-31 0000899923 us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Member 2015-12-31 0000899923 us-gaap:MunicipalBondsMember 2015-12-31 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2015-12-31 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0000899923 2015-12-31 0000899923 2014-12-31 0000899923 us-gaap:CashMember 2015-06-30 0000899923 us-gaap:CorporateDebtSecuritiesMember 2015-06-30 0000899923 us-gaap:USTreasuryAndGovernmentMember 2015-06-30 0000899923 us-gaap:CashEquivalentsMember 2015-06-30 0000899923 us-gaap:MunicipalBondsMember 2015-06-30 0000899923 us-gaap:CashAndCashEquivalentsMember 2015-06-30 0000899923 mygn:InProcessResearchAndDevelopmentWithIndefiniteLivesMember 2015-06-30 0000899923 mygn:PurchasedLicensesAndTechnologiesMember 2015-06-30 0000899923 us-gaap:CustomerRelationshipsMember 2015-06-30 0000899923 us-gaap:TrademarksMember 2015-06-30 0000899923 us-gaap:FairValueInputsLevel2Member 2015-06-30 0000899923 us-gaap:FairValueInputsLevel1Member 2015-06-30 0000899923 us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member 2015-06-30 0000899923 us-gaap:CorporateDebtSecuritiesMember 2015-06-30 0000899923 us-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member 2015-06-30 0000899923 us-gaap:USTreasuryAndGovernmentMember 2015-06-30 0000899923 us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member 2015-06-30 0000899923 us-gaap:MoneyMarketFundsMember 2015-06-30 0000899923 us-gaap:MunicipalBondsMemberus-gaap:FairValueInputsLevel2Member 2015-06-30 0000899923 us-gaap:MunicipalBondsMember 2015-06-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2015-06-30 0000899923 2015-06-30 0000899923 2014-06-30 0000899923 mygn:EmployeeDirectorAndConsultantEquityIncentivePlanMember 2015-12-30 0000899923 mygn:EmployeeDirectorAndConsultantEquityIncentivePlanMember 2015-12-03 0000899923 mygn:SeventhShareRepurchaseProgramMember 2015-02-28 0000899923 mygn:GermanClinicMember 2015-02-27 iso4217:USD shares iso4217:USD shares mygn:plan pure mygn:Segment Money market funds are primarily comprised of exchange traded funds and accrued interest

EX-101.SCH 7 mygn-20151231.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - Condensed Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 106 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 107 - Statement - Condensed Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - Acquisitions link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - Marketable Investment Securities link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - Property, Plant and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - Goodwill and Intangible Assets link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - Cost Basis Investment link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - Accrued Liabilities link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - Other Long Term Liabilities link:calculationLink link:presentationLink link:definitionLink 116 - Disclosure - Preferred and Common Stockholder's Equity link:calculationLink link:presentationLink link:definitionLink 117 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 118 - Disclosure - Share-Based Compensation link:calculationLink link:presentationLink link:definitionLink 119 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 120 - Disclosure - Commitment and Contingencies link:calculationLink link:presentationLink link:definitionLink 121 - Disclosure - Employee Deferred Savings Plan link:calculationLink link:presentationLink link:definitionLink 122 - Disclosure - Segment and Related Information link:calculationLink link:presentationLink link:definitionLink 123 - Disclosure - Supplemental Cash Flow Information link:calculationLink link:presentationLink link:definitionLink 124 - Disclosure - Acquisitions (Tables) link:calculationLink link:presentationLink link:definitionLink 125 - Disclosure - Marketable Investment Securities (Tables) link:calculationLink link:presentationLink link:definitionLink 126 - Disclosure - Property, Plant and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 127 - Disclosure - Goodwill and Intangible Assets (Tables) link:calculationLink link:presentationLink link:definitionLink 128 - Disclosure - Accrued Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 129 - Disclosure - Other Long Term Liabilities (Tables) link:calculationLink link:presentationLink link:definitionLink 130 - Disclosure - Preferred and Common Stockholder's Equity (Tables) link:calculationLink link:presentationLink link:definitionLink 131 - Disclosure - Share-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 132 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 133 - Disclosure - Employee Deferred Savings Plan (Tables) link:calculationLink link:presentationLink link:definitionLink 134 - Disclosure - Segment and Related Information (Tables) link:calculationLink link:presentationLink link:definitionLink 135 - Disclosure - Supplemental Cash Flow Information (Tables) link:calculationLink link:presentationLink link:definitionLink 136 - Disclosure - Acquisitions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 137 - Disclosure - Acquisitions - Allocation of Consideration Transferred (Detail) link:calculationLink link:presentationLink link:definitionLink 138 - Disclosure - Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) link:calculationLink link:presentationLink link:definitionLink 139 - Disclosure - Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities (Detail) link:calculationLink link:presentationLink link:definitionLink 140 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) link:calculationLink link:presentationLink link:definitionLink 141 - Disclosure - Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 142 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 143 - Disclosure - Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) link:calculationLink link:presentationLink link:definitionLink 144 - Disclosure - Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 145 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 146 - Disclosure - Cost Basis Investment - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 147 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 148 - Disclosure - Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 149 - Disclosure - Other Long Term Liabilities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 150 - Disclosure - Preferred and Common Stockholder's Equity - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 151 - Disclosure - Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 152 - Disclosure - Preferred and Common Stockholder's Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) link:calculationLink link:presentationLink link:definitionLink 153 - Disclosure - Preferred and Common Stockholder's Equity - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) link:calculationLink link:presentationLink link:definitionLink 154 - Disclosure - Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) link:calculationLink link:presentationLink link:definitionLink 155 - Disclosure - Income Taxes - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 156 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 157 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 158 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 159 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) link:calculationLink link:presentationLink link:definitionLink 160 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 161 - Disclosure - Employee Deferred Savings Plan - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 162 - Disclosure - Employee Deferred Savings Plan - Company's Recorded Contributions To Plan (Detail) link:calculationLink link:presentationLink link:definitionLink 163 - Disclosure - Segment and Related Information - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 164 - Disclosure - Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 165 - Disclosure - Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) link:calculationLink link:presentationLink link:definitionLink 166 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 mygn-20151231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 mygn-20151231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 mygn-20151231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounting Policies [Abstract] Accounting Policies [Abstract] Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accrued Liabilities Accounts Payable, Current Accounts payable Accounts Receivable, Net, Current Trade accounts receivable, less allowance for doubtful accounts of $6.2 December 31, 2015 and $7.6 June 30, 2015 Accrued Liabilities, Current Accrued liabilities Total Accrued liabilities Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive loss Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Intangible asset amortization period for income tax purposes Additional Paid in Capital, Common Stock Additional paid-in capital Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Other Segments [Member] Other Allowance for Doubtful Accounts Receivable, Current Allowance for doubtful accounts Amendment Flag Amendment Flag Amortization of Intangible Assets Amortization of intangible assets Amount Charged To Retained Earnings As A Result Of Stock Repurchases. Amount Charged To Retained Earnings As Result Of Stock Repurchases Charges to retained earnings Amount Of Reduction In Common Stock As A Result Of Stock Repurchases Amount Of Reduction In Common Stock As Result Of Stock Repurchases Common stock and additional paid-in-capital reductions Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive options and RSU's excluded from EPS computation Assets Total assets Assets [Abstract] ASSETS Assets, Current Total current assets Assets, Current [Abstract] Current assets: Assets, Fair Value Adjustment Fair value adjustment on marketable investment securities recorded to stockholders' equity Assets, Fair Value Disclosure Total fair value of financial assets Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized holding gains Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax Gross unrealized holding losses Available-for-sale Securities Estimated fair value Available-for-sale Securities, Amortized Cost Basis Amortized cost Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Amortized Cost Basis Due after five years, Amortized cost Available-for-sale Securities, Debt Maturities, Year Six Through Ten, Fair Value Due after five years, Estimated fair value Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Due after one year through five years, Amortized cost Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Due after one year through five years, Estimated fair value Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Due within one year, Amortized cost Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Due within one year, Estimated fair value Award Date [Axis] Award Date [Axis] Award Date [Domain] Award Date [Domain] Award Type [Axis] Award Type [Axis] Basis of Accounting [Text Block] Basis of Presentation Buildings and Improvements, Gross Buildings and improvements Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition Schedule Of Consideration Transferred [Table Text Block] Business Acquisition Schedule Of Consideration Transferred [Table Text Block] Allocation of Consideration Transferred Business Combination, Consideration Transferred Total consideration transferred Business Combination Disclosure [Text Block] Acquisitions Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Current assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities Current liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equipment Equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Land Real property Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Long-term liabilities Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Total purchase price Business Combinations [Abstract] Business Combinations [Abstract] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of the period Cash and cash equivalents at beginning of the period Cash equivalents, Amortized cost Amortized cost Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Cash equivalents, Estimated fair value Estimated fair value Cash and Cash Equivalents [Member] Total Cash and Cash Equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net increase (decrease) in cash and cash equivalents Cash Equivalents [Member] Cash Equivalents Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: Cash Flow, Supplemental Disclosures [Text Block] Supplemental Cash Flow Information Cash [Member] Cash Class of Stock [Line Items] Class of Stock [Line Items] Commitments and Contingencies Commitments and contingencies Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitment and Contingencies Common Stock [Member] Common Stock Common Stock, Par or Stated Value Per Share Common stock, par value Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock issued, Ending balance Common stock issued, Beginning balance Common stock, shares issued Common Stock, Shares, Outstanding Common stock outstanding, Ending balance Common stock outstanding, Beginning balance Common stock, shares outstanding Common Stock, Value, Issued Common stock, 71.6 and 68.9 shares outstanding at December 31, 2015 and June 30, 2015 respectively Compensation and Employee Benefit Plans [Text Block] Employee Deferred Savings Plan Compensation and Retirement Disclosure [Abstract] Compensation and Retirement Disclosure [Abstract] Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income Corporate Debt Securities [Member] Corporate Bonds and Notes Cost Method Investments Investment accounted under cost method Cost-method Investments, Description [Text Block] Cost Basis Investment Primary financial statement caption in which the reported facts about the cost of molecular diagnostic testing expense have been included. Cost Of Molecular Diagnostic Testing [Member] Molecular Diagnostic Testing Expense The aggregate cost of goods produced and sold and services rendered for Pharmaceutical and Clinical Services. Cost Of Pharmaceutical And Clinical Services Cost of pharmaceutical and clinical services Primary financial statement caption in which the reported facts about the cost of pharmaceutical and clinical services expense have been included. Cost of Pharmaceutical and Clinical Services [Member] Pharmaceutical and Clinical Services Expense Cost of Revenue Cost of molecular diagnostic testing Costs and Expenses Total costs and expenses Current Fiscal Year End Date Current Fiscal Year End Date Customer Relationships [Member] Customer Relationships Deferred Revenue, Current Deferred revenue Deferred Tax Assets, Net of Valuation Allowance, Current Deferred taxes Deferred Tax Assets, Net of Valuation Allowance, Noncurrent Non-current deferred tax assets Deferred Tax Liabilities, Net, Noncurrent Long-term deferred taxes Defined Benefit Pension Plan, Liabilities, Noncurrent Net pension liability Pension obligation Defined Benefit Plan, Contributions by Employer Deferred savings plan Company contributions Defined Benefit Plan, Fair Value of Plan Assets Fair value of plan assets Depreciation Depreciation expense Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Diagnostics [Member] Diagnostics [Member] Diagnostics Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Share-Based Compensation Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share, Basic Basic Earnings Per Share, Basic and Diluted [Abstract] Earnings per share: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted average shares outstanding: Earnings Per Share, Diluted Diluted Effective Income Tax Rate Reconciliation, Percent Approximate rate on pre-tax income Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent U.S. federal statutory rate Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations Effect of foreign exchange rates on cash and cash equivalents Eligible Item or Group for Fair Value Option [Axis] Eligible Item or Group for Fair Value Option [Axis] Employee Director And Consultant Equity Incentive Plan [Member] Employee Director And Consultant Equity Incentive Plan [Member] The 2010 Plan Employee-related Liabilities, Current Employee compensation and benefits Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Total unrecognized share-based compensation cost, weighted-average period, years Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Total unrecognized share-based compensation cost related to RSUs Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Total unrecognized share-based compensation cost related to stock options Employee Stock Option [Member] Stock options Employee Stock Purchase Plan Twenty Twelve [Member] Employee Stock Purchase Plan Twenty Twelve [Member] 2012 Purchase Plan Employers Contribution Not To Exceed Percentage Of The Employees Compensation Employers Contribution Not To Exceed Percentage Of Employees Compensation Employer's contribution not to exceed percentage of the employees compensation Entity Central Index Key Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Equity [Abstract] Equity [Abstract] Equity Component [Domain] Equity Component [Domain] Investment, Name [Domain] Investment, Name [Domain] Excess Tax Benefit from Share-based Compensation, Financing Activities Excess tax benefit from share-based compensation Excess Tax Benefit from Share-based Compensation, Operating Activities Excess tax benefit from share-based compensation Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block] Schedule of Fair Value of Financial Assets Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Measurements Fair Value, Inputs, Level 1 [Member] Level 1 Fair Value, Inputs, Level 2 [Member] Level 2 Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Option, Eligible Item or Group [Domain] Fair Value, Option, Eligible Item or Group [Domain] Fair Value, Option, Qualitative Disclosures Related to Election [Line Items] Fair Value, Option, Qualitative Disclosures Related to Election [Line Items] Fair Value, Option, Qualitative Disclosures Related to Election [Table] Fair Value, Option, Qualitative Disclosures Related to Election [Table] Finite-Lived Intangible Assets, Accumulated Amortization Accumulated Amortization Finite-lived Intangible Assets Amortization Expense [Table Text Block] Amortization for Intangible Assets Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Gross Gross Carrying Amount, amortizable intangible assets Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Net Net, amortizable intangible assets Foreign Currency Transaction Gain, before Tax Gain on remeasurement of foreign currency Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Gain on disposition of assets German Clinic [Member] German Clinic [Member] German Clinic [Member] Goodwill Ending balance Beginning balance Goodwill Goodwill, Acquired During Period Acquisitions Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Line Items] Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Goodwill And Intangible Assets [Table] Goodwill, Translation Adjustments Translation adjustments Other than Temporary Impairment Losses, Investments Impairment on investment Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Income before income tax Income Statement [Abstract] Income Statement [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Text Block] Income Taxes Income Taxes Paid Cash paid during the period for income taxes Income Tax Expense (Benefit) Income tax expense Income tax provision Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Receivable Trade accounts receivable Increase (Decrease) in Accrued Liabilities Accrued liabilities Increase (Decrease) in Deferred Income Taxes Deferred income taxes Increase (Decrease) in Deferred Revenue Deferred revenue Increase (Decrease) in Inventories Inventory Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities: Increase (Decrease) in Other Receivables Other receivables Increase (Decrease) in Prepaid Expense Prepaid expenses Increase (Decrease) in Prepaid Taxes Prepaid taxes Increase (Decrease) in Restricted Cash Restricted cash Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets (Excluding Goodwill) Net, non-amortizable intangible assets Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] In Process Research And Development With Indefinite Lives [Member] In Process Research And Development With Indefinite Lives [Member] In-Process Research and Development Intangible Assets, Gross (Excluding Goodwill) Gross Carrying Amount, total intangible assets Intangible Assets [Line Items] Intangible Assets [Line Items] Intangible Assets [Line Items] Intangible Assets, Net (Excluding Goodwill) Intangibles, net Net, total intangible assets Inventory, Net Inventory Investment Income, Interest Interest income Investments, All Other Investments [Abstract] Investments, All Other Investments [Abstract] Investments and Cash Amortized cost Total Investments and cash at fair value. Investments And Cash At Fair Value Estimated fair value Total Investments Classified by Contractual Maturity Date [Table Text Block] Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Marketable Investment Securities Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Land Land Leasehold Improvements, Gross Leasehold improvements Liabilities Total liabilities Liabilities and Equity Total liabilities and stockholders' equity Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities, Current Total current liabilities EX-101.PRE 11 mygn-20151231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Dec. 31, 2015	Jan. 29, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q2
Trading Symbol	MYGN
Entity Registrant Name	MYRIAD GENETICS INC
Entity Central Index Key	0000899923
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		71,252,152

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 134.7	$ 64.1
Marketable investment securities	84.6	80.7
Prepaid expenses	9.7	12.5
Inventory	29.1	25.1
Trade accounts receivable, less allowance for doubtful accounts of $6.2 December 31, 2015 and $7.6 June 30, 2015	84.3	85.8
Deferred taxes		13.5
Prepaid taxes	28.0
Other receivables	5.1	1.9
Total current assets	375.5	283.6
Property, plant and equipment, net	61.7	67.2
Long-term marketable investment securities	66.2	40.6
Intangibles, net	186.3	192.6
Goodwill	177.0	177.2
Other assets	5.0	5.0
Total assets	871.7	766.2
Current liabilities:
Accounts payable	16.5	21.1
Accrued liabilities	47.9	46.1
Deferred revenue	1.5	1.5
Total current liabilities	65.9	68.7
Unrecognized tax benefits	27.9	26.4
Other long-term liabilities	6.8	8.8
Long-term deferred taxes	0.3	0.2
Total liabilities	$ 100.9	$ 104.1
Commitments and contingencies
Stockholders' equity:
Common stock, 71.6 and 68.9 shares outstanding at December 31, 2015 and June 30, 2015 respectively	$ 0.7	$ 0.7
Additional paid-in capital	847.8	745.4
Accumulated other comprehensive loss	(9.1)	(7.0)
Accumulated deficit	(68.6)	(77.0)
Total stockholders' equity	770.8	662.1
Total liabilities and stockholders' equity	$ 871.7	$ 766.2

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 6.2	$ 7.6
Common stock, shares outstanding	71.6	68.9

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Molecular diagnostic testing	$ 182.6	$ 179.2	$ 354.5	$ 343.6
Pharmaceutical and clinical services	10.7	5.2	22.3	9.6
Total revenue	193.3	184.4	376.8	353.2
Costs and expenses:
Cost of molecular diagnostic testing	34.1	35.1	65.0	67.8
Cost of pharmaceutical and clinical services	6.5	2.8	12.1	4.9
Research and development expense	16.7	17.5	33.9	40.1
Selling, general, and administrative expense	90.8	92.7	177.3	178.1
Total costs and expenses	148.1	148.1	288.3	290.9
Operating income	45.2	36.3	88.5	62.3
Other income (expense):
Interest income	0.1	0.1	0.2	0.1
Other	(0.3)	1.5	(0.1)	1.4
Total other income (expense):	(0.2)	1.6	0.1	1.5
Income before income tax	45.0	37.9	88.6	63.8
Income tax provision	14.7	13.9	31.6	23.8
Net income	$ 30.3	$ 24.0	$ 57.0	$ 40.0
Earnings per share:
Basic	$ 0.43	$ 0.33	$ 0.82	$ 0.55
Diluted	$ 0.41	$ 0.32	$ 0.78	$ 0.53
Weighted average shares outstanding:
Basic	70.5	72.5	69.6	72.6
Diluted	73.8	75.4	73.1	75.8

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 30.3	$ 24.0	$ 57.0	$ 40.0
Unrealized gain (loss) on available-for-sale securities, net of tax	(0.2)	(0.1)	(0.1)	(0.3)
Change in foreign currency translation adjustment, net of tax	(1.8)	(1.7)	(2.0)	(2.4)
Comprehensive income	$ 28.3	$ 22.2	$ 54.9	$ 37.3

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 57.0	$ 40.0
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	13.5	12.0
Gain on disposition of assets	(0.4)
Share-based compensation expense	16.3	19.0
Bad debt expense	14.5	14.0
Deferred income taxes	29.8	1.9
Unrecognized tax benefits	1.5	1.1
Excess tax benefit from share-based compensation	(16.1)	(2.6)
Gain on remeasurement of foreign currency		(0.5)
Changes in assets and liabilities:
Prepaid expenses	2.8	(0.8)
Trade accounts receivable	(11.1)	(13.9)
Other receivables	(5.3)	(1.6)
Inventory	(4.1)	3.7
Prepaid taxes	(28.0)	8.0
Accounts payable	(4.1)	(6.2)
Accrued liabilities	(0.5)	(15.2)
Deferred revenue		0.7
Net cash provided by operating activities	65.8	59.6
CASH FLOWS FROM INVESTING ACTIVITIES
Capital expenditures	(2.1)	(17.5)
Restricted cash		(21.6)
Purchases of marketable investment securities	(100.7)	(22.6)
Proceeds from maturities and sales of marketable investment securities	71.3	80.5
Net cash provided by (used in) investing activities	(31.5)	18.8
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from common stock issued under share-based compensation plans	84.9	20.2
Excess tax benefit from share-based compensation	16.1	2.6
Repurchase and retirement of common stock	(62.9)	(103.9)
Net cash provided by (used in) financing activities	38.1	(81.1)
Effect of foreign exchange rates on cash and cash equivalents	(1.8)	(2.4)
Net increase (decrease) in cash and cash equivalents	70.6	(5.1)
Cash and cash equivalents at beginning of the period	64.1	64.8
Cash and cash equivalents at end of the period	$ 134.7	$ 59.7

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

6 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Basis of Presentation

(1)

BASIS OF PRESENTATION

XML 19 R8.htm IDEA: XBRL DOCUMENT

Acquisitions

6 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Acquisitions

(2)

ACQUISITIONS

German Clinic


	Estimated Fair Value
Current assets	$	3.1
Real property		20.7
Equipment		1.6
Goodwill		8.1
Current liabilities		(4.4	)
Long-term liabilities		(9.0	)

Total purchase price	$	20.1

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Marketable Investment Securities

6 Months Ended

Dec. 31, 2015

Investments, Debt and Equity Securities [Abstract]

Marketable Investment Securities

(3)

MARKETABLE INVESTMENT SECURITIES


	Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses			Estimated fair value
At December 31, 2015:
Cash and cash equivalents:
Cash	$	114.0	$	—	$	—		$	114.0
Cash equivalents		20.7		—		—			20.7

Total cash and cash equivalents		134.7		—		—			134.7

Available-for-sale:
Corporate bonds and notes		45.5		—		(0.1	)		45.4
Municipal bonds		66.5		0.1		(0.1	)		66.5
Federal agency issues		38.9		—		—			38.9

Total	$	285.6	$	0.1	$	(0.2	)	$	285.5


	Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses			Estimated fair value
At June 30, 2015:
Cash and cash equivalents:
Cash	$	54.7	$	—	$	—		$	54.7
Cash equivalents		9.4		—		—			9.4

Total cash and cash equivalents		64.1		—		—			64.1

Available-for-sale:
Corporate bonds and notes		41.8		—		—			41.8
Municipal bonds		66.3		0.1		(0.1	)		66.3
Federal agency issues		13.2		—		—			13.2

Total	$	185.4	$	0.1	$	(0.1	)	$	185.4

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2015:


	Amortized cost		Estimated fair value
Cash	$	114.0	$	114.0
Cash equivalents		20.7		20.7
Available-for-sale:
Due within one year		84.6		84.6
Due after one year through five years		66.3		66.2
Due after five years		—		—

Total	$	285.6	$	285.5

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

XML 21 R10.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net

6 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment, Net

(4)

PROPERTY, PLANT AND EQUIPMENT, NET


	December 31, 2015			June 30, 2015
Land	$	2.3		$	2.3
Buildings and improvements		17.3			18.2
Leasehold improvements		18.6			18.5
Equipment		101.0			99.1

		139.2			138.1
Less accumulated depreciation		(77.5	)		(70.9	)

Property, plant and equipment, net	$	61.7		$	67.2

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Depreciation expense

3.6

2.9

7.2

5.5

XML 22 R11.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets

6 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

(5)

GOODWILL AND INTANGIBLE ASSETS

Goodwill


	Carrying amount
Beginning balance July 1, 2015	$	177.2
Acquisitions		—
Translation adjustments		(0.2	)

Ending balance December 31, 2015	$	177.0

Intangible Assets


At December 31, 2015:	Gross Carrying Amount		Accumulated Amortization			Net
Purchased licenses and technologies	$	199.1	$	(22.6	)	$	176.5
Customer relationships		4.7		(2.2	)		2.5
Trademarks		3.0		(0.5	)		2.5

Total amortized intangible assets		206.8		(25.3	)		181.5

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(25.3	)	$	186.3


At June 30, 2015:	Gross Carrying Amount		Accumulated Amortization			Net
Purchased licenses and technologies	$	199.1	$	(16.7	)	$	182.4
Customer relationships		4.7		(1.9	)		2.8
Trademarks		3.0		(0.4	)		2.6

Total amortized intangible assets		206.8		(19.0	)		187.8

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(19.0	)	$	192.6

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Amortization of intangible assets

3.2

3.1

6.3

6.5

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Cost Basis Investment

6 Months Ended

Dec. 31, 2015

Investments, All Other Investments [Abstract]

Cost Basis Investment

(6)

COST BASIS INVESTMENT

XML 24 R13.htm IDEA: XBRL DOCUMENT

Accrued Liabilities

6 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Accrued Liabilities

(7)

ACCRUED LIABILITIES


	December 31, 2015		June 30, 2015
Employee compensation and benefits	$	34.4	$	33.8
Accrued taxes payable		4.7		3.8
Other		8.8		8.5

Total Accrued liabilities	$	47.9	$	46.1

XML 25 R14.htm IDEA: XBRL DOCUMENT

Other Long Term Liabilities

6 Months Ended

Dec. 31, 2015

Other Liabilities Disclosure [Abstract]

Other Long Term Liabilities

(8)

OTHER LONG TERM LIABILITIES


	December 31, 2015		June 30, 2015
Pension obligation	$	4.8	$	4.9
Other		2.0		3.9

Total other long term liabilities	$	6.8	$	8.8

XML 26 R15.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity

6 Months Ended

Dec. 31, 2015

Equity [Abstract]

Preferred and Common Stockholder's Equity

(9)

PREFERRED AND COMMON STOCKHOLDER’S EQUITY

The Company is authorized to issue up to 5.0 shares of preferred stock, par value $0.01 per share. There were no preferred shares outstanding at December 31, 2015.

The Company is authorized to issue up to 150.0 shares of common stock, par value $0.01 per share. There were 71.6 shares issued and outstanding at December 31, 2015.

Common shares issued and outstanding


	Six months ended December 31,
	2015			2014
Common stock issued and outstanding at July 1		68.9			73.5
Common stock issued upon exercise of options and employee stock plans		4.4			1.0
Repurchase and retirement of common stock		(1.7	)		(3.0	)

Common stock issued and outstanding at December 31		71.6			71.5

The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Denominator:
Weighted-average shares outstanding used to compute basic EPS		70.5		72.5		69.6		72.6
Effect of dilutive shares		3.3		2.9		3.5		3.2

Weighted-average shares outstanding and dilutive securities used to compute diluted EPS		73.8		75.4		73.1		75.8

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Anti-dilutive options and RSU’s excluded from EPS computation

—

0.9

—

Stock Repurchase Program


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Shares purchased and retired		0.6		1.7		1.7		3.0
Common stock and additional paid-in-capital reductions	$	5.4	$	14.8		14.9	$	25.0
Charges to retained earnings	$	20.0	$	43.6		48.5	$	79.0

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

XML 27 R16.htm IDEA: XBRL DOCUMENT

Income Taxes

6 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

(10)

INCOME TAXES

XML 28 R17.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

6 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Share-Based Compensation

(11)

SHARE-BASED COMPENSATION

Stock Options

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2015 is as follows:


	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2015		12.5		$	23.49
Options granted		—		$	—
Less:
Options exercised		(4.0	)	$	21.38
Options canceled or expired		—		$	—

Options outstanding at December 31, 2015		8.5		$	24.50

Options exercisable at December 31, 2015		6.9		$	24.00

As of December 31, 2015, there was $10.8 of total unrecognized share-based compensation expense related to stock options that will be recognized over a weighted-average period of 1.34 years.

Restricted Stock Units

A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2015 is as follows:


	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2015		1.0		$	37.63
RSUs granted		0.8		$	40.66
Less:
RSUs vested		(0.3	)	$	39.74
RSUs canceled		—		$	—

RSUs outstanding at December 31, 2015		1.5		$	38.80

As of December 31, 2015, there was $39.0 of total unrecognized share-based compensation expense related to RSUs that will be recognized over a weighted-average period of 2.79 years.

This unrecognized compensation expense is equal to the fair value of RSUs expected to vest.

Employee Stock Purchase Plan

Share-Based Compensation Expense

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Cost of molecular diagnostic testing	$	0.3	$	0.2	$	0.5	$	0.4
Cost of pharmaceutical and clinical services		0.1		0.1		0.2		0.3
Research and development expense		1.2		1.3		2.8		2.0
Selling, general, and administrative expense		6.1		10.5		12.8		16.3

Total share-based compensation expense	$	7.7	$	12.1	$	16.3	$	19.0

XML 29 R18.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

6 Months Ended

Dec. 31, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

(12)

FAIR VALUE MEASUREMENTS


Level 1	—	quoted prices in active markets for identical assets and liabilities.

Level 2	—	observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company’s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.

Level 3	—	unobservable inputs.


	Level 1		Level 2		Level 3		Total
at December 31, 2015
Money market funds (a)	$	1.1	$	—	$	—	$	1.1
Corporate bonds and notes		—		59.6		—		59.6
Municipal bonds		—		66.5		—		66.5
Federal agency issues		—		44.3		—		44.3

Total	$	1.1	$	170.4	$	—	$	171.5

(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest


	Level 1		Level 2		Level 3		Total
at June 30, 2015
Money market funds (a)	$	2.4	$	—	$	—	$	2.4
Corporate bonds and notes		—		44.8		—		44.8
Municipal bonds		—		70.3		—		70.3
Federal agency issues		—		13.2		—		13.2

Total	$	2.4	$	128.3	$	—	$	130.7

(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 30 R19.htm IDEA: XBRL DOCUMENT

Commitment and Contingencies

6 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitment and Contingencies

(13)

COMMITMENTS AND CONTINGENCIES

XML 31 R20.htm IDEA: XBRL DOCUMENT

Employee Deferred Savings Plan

6 Months Ended

Dec. 31, 2015

Postemployment Benefits [Abstract]

Employee Deferred Savings Plan

(14)

EMPLOYEE DEFERRED SAVINGS PLAN


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Deferred savings plan Company contributions	$	1.2	$	1.1	$	2.7	$	2.5

XML 32 R21.htm IDEA: XBRL DOCUMENT

Segment and Related Information

6 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Segment and Related Information

(15)

SEGMENT AND RELATED INFORMATION

Segment revenue and operating income (loss) were as follows during the periods presented:


	Diagnostics		Other			Total
Three months ended December 31, 2015
Revenues	$	182.6	$	10.7		$	193.3
Depreciation and amortization		5.5		1.3			6.8
Segment operating income (loss)		64.6		(19.4	)		45.2
Three months ended December 31, 2014
Revenues	$	179.2	$	5.2		$	184.4
Depreciation and amortization		5.0		1.0			6.0
Segment operating income (loss)		59.0		(22.7	)		36.3
Six months ended December 31, 2015
Revenues	$	354.5	$	22.3		$	376.8
Depreciation and amortization		10.9		2.6			13.5
Segment operating income (loss)		127.0		(38.5	)		88.5
Six months ended December 31, 2014
Revenues	$	343.6	$	9.6		$	353.2
Depreciation and amortization		10.0		2.0			12.0
Segment operating income (loss)		104.1		(41.8	)		62.3


	Three months ended December 31,					Six months ended December 31,
	2015			2014		2015			2014
Total operating income for reportable segments	$	45.2		$	36.3	$	88.5		$	62.3
Unallocated amounts:
Interest income		0.1			0.1		0.2			0.1
Other		(0.3	)		1.5		(0.1	)		1.4

Income from operations before income taxes		45.0			37.9		88.6			63.8

Income tax provision		14.7			13.9		31.6			23.8

Net income	$	30.3		$	24.0	$	57.0		$	40.0

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 33 R22.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information

6 Months Ended

Dec. 31, 2015

Supplemental Cash Flow Elements [Abstract]

Supplemental Cash Flow Information

(16)

SUPPLEMENTAL CASH FLOW INFORMATION


	Six months ended December 31,
	2015			2014
Cash paid during the period for income taxes	$	28.5		$	12.8
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders’ equity	$	(0.2	)	$	(0.1	)

XML 34 R23.htm IDEA: XBRL DOCUMENT

Acquisitions (Tables)

6 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Allocation of Consideration Transferred

The Company expects the allocation of the consideration transferred to be final within the measurement period (up to one year from the acquisition date).


	Estimated Fair Value
Current assets	$	3.1
Real property		20.7
Equipment		1.6
Goodwill		8.1
Current liabilities		(4.4	)
Long-term liabilities		(9.0	)

Total purchase price	$	20.1

XML 35 R24.htm IDEA: XBRL DOCUMENT

Marketable Investment Securities (Tables)

6 Months Ended

Dec. 31, 2015

Investments, Debt and Equity Securities [Abstract]

Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security

The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale securities by major security type and class of security at December 31, 2015 and June 30, 2015 were as follows:


	Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses			Estimated fair value
At December 31, 2015:
Cash and cash equivalents:
Cash	$	114.0	$	—	$	—		$	114.0
Cash equivalents		20.7		—		—			20.7

Total cash and cash equivalents		134.7		—		—			134.7

Available-for-sale:
Corporate bonds and notes		45.5		—		(0.1	)		45.4
Municipal bonds		66.5		0.1		(0.1	)		66.5
Federal agency issues		38.9		—		—			38.9

Total	$	285.6	$	0.1	$	(0.2	)	$	285.5


	Amortized cost		Gross unrealized holding gains		Gross unrealized holding losses			Estimated fair value
At June 30, 2015:
Cash and cash equivalents:
Cash	$	54.7	$	—	$	—		$	54.7
Cash equivalents		9.4		—		—			9.4

Total cash and cash equivalents		64.1		—		—			64.1

Available-for-sale:
Corporate bonds and notes		41.8		—		—			41.8
Municipal bonds		66.3		0.1		(0.1	)		66.3
Federal agency issues		13.2		—		—			13.2

Total	$	185.4	$	0.1	$	(0.1	)	$	185.4

Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities

Cash, cash equivalents, and maturities of debt securities classified as available-for-sale securities are as follows at December 31, 2015:


	Amortized cost		Estimated fair value
Cash	$	114.0	$	114.0
Cash equivalents		20.7		20.7
Available-for-sale:
Due within one year		84.6		84.6
Due after one year through five years		66.3		66.2
Due after five years		—		—

Total	$	285.6	$	285.5

XML 36 R25.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net (Tables)

6 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Schedule of Property, Plant and Equipment, Net


	December 31, 2015			June 30, 2015
Land	$	2.3		$	2.3
Buildings and improvements		17.3			18.2
Leasehold improvements		18.6			18.5
Equipment		101.0			99.1

		139.2			138.1
Less accumulated depreciation		(77.5	)		(70.9	)

Property, plant and equipment, net	$	61.7		$	67.2

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Depreciation expense

3.6

2.9

7.2

5.5

XML 37 R26.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Tables)

6 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Changes in Carrying Amount of Goodwill

The following summarizes changes to the goodwill balance for the six months ended December 31, 2015:


	Carrying amount
Beginning balance July 1, 2015	$	177.2
Acquisitions		—
Translation adjustments		(0.2	)

Ending balance December 31, 2015	$	177.0

Summarized Amounts Reported as Intangible Assets

The following summarizes the amounts reported as intangible assets:


At December 31, 2015:	Gross Carrying Amount		Accumulated Amortization			Net
Purchased licenses and technologies	$	199.1	$	(22.6	)	$	176.5
Customer relationships		4.7		(2.2	)		2.5
Trademarks		3.0		(0.5	)		2.5

Total amortized intangible assets		206.8		(25.3	)		181.5

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(25.3	)	$	186.3


At June 30, 2015:	Gross Carrying Amount		Accumulated Amortization			Net
Purchased licenses and technologies	$	199.1	$	(16.7	)	$	182.4
Customer relationships		4.7		(1.9	)		2.8
Trademarks		3.0		(0.4	)		2.6

Total amortized intangible assets		206.8		(19.0	)		187.8

In-process research and development		4.8		—			4.8

Total unamortized intangible assets		4.8		—			4.8

Total intangible assets	$	211.6	$	(19.0	)	$	192.6

Amortization for Intangible Assets

The Company recorded amortization expense during the respective periods for these intangible assets as follows:

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Amortization of intangible assets

3.2

3.1

6.3

6.5

XML 38 R27.htm IDEA: XBRL DOCUMENT

Accrued Liabilities (Tables)

6 Months Ended

Dec. 31, 2015

Payables and Accruals [Abstract]

Summary of Accrued Liabilities


	December 31, 2015		June 30, 2015
Employee compensation and benefits	$	34.4	$	33.8
Accrued taxes payable		4.7		3.8
Other		8.8		8.5

Total Accrued liabilities	$	47.9	$	46.1

XML 39 R28.htm IDEA: XBRL DOCUMENT

Other Long Term Liabilities (Tables)

6 Months Ended

Dec. 31, 2015

Other Liabilities Disclosure [Abstract]

Summary of Other Long Term Liabilities


	December 31, 2015		June 30, 2015
Pension obligation	$	4.8	$	4.9
Other		2.0		3.9

Total other long term liabilities	$	6.8	$	8.8

XML 40 R29.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity (Tables)

6 Months Ended

Dec. 31, 2015

Equity [Abstract]

Summary of Common Shares Issued and Outstanding

Common shares issued and outstanding


	Six months ended December 31,
	2015			2014
Common stock issued and outstanding at July 1		68.9			73.5
Common stock issued upon exercise of options and employee stock plans		4.4			1.0
Repurchase and retirement of common stock		(1.7	)		(3.0	)

Common stock issued and outstanding at December 31		71.6			71.5

Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations

The following is a reconciliation of the denominators of the basic and diluted earnings per share (“EPS”) computations:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Denominator:
Weighted-average shares outstanding used to compute basic EPS		70.5		72.5		69.6		72.6
Effect of dilutive shares		3.3		2.9		3.5		3.2

Weighted-average shares outstanding and dilutive securities used to compute diluted EPS		73.8		75.4		73.1		75.8

Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation

These potential dilutive common shares, which may be dilutive to future diluted earnings per share, are as follows:

Three months ended
December 31,

Six months ended
December 31,

2015

2014

2015

2014

Anti-dilutive options and RSU’s excluded from EPS computation

—

0.9

—

Schedule of Stock Repurchases

The shares retired, aggregate common stock and additional paid-in capital reductions, and related charges to accumulated deficit for the repurchases for periods ended December 31, 2015 and 2014 were as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Shares purchased and retired		0.6		1.7		1.7		3.0
Common stock and additional paid-in-capital reductions	$	5.4	$	14.8		14.9	$	25.0
Charges to retained earnings	$	20.0	$	43.6		48.5	$	79.0

XML 41 R30.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

6 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the six months ended December 31, 2015 is as follows:


	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2015		12.5		$	23.49
Options granted		—		$	—
Less:
Options exercised		(4.0	)	$	21.38
Options canceled or expired		—		$	—

Options outstanding at December 31, 2015		8.5		$	24.50

Options exercisable at December 31, 2015		6.9		$	24.00

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the six months ended December 31, 2015 is as follows:


	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2015		1.0		$	37.63
RSUs granted		0.8		$	40.66
Less:
RSUs vested		(0.3	)	$	39.74
RSUs canceled		—		$	—

RSUs outstanding at December 31, 2015		1.5		$	38.80

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Cost of molecular diagnostic testing	$	0.3	$	0.2	$	0.5	$	0.4
Cost of pharmaceutical and clinical services		0.1		0.1		0.2		0.3
Research and development expense		1.2		1.3		2.8		2.0
Selling, general, and administrative expense		6.1		10.5		12.8		16.3

Total share-based compensation expense	$	7.7	$	12.1	$	16.3	$	19.0

XML 42 R31.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

6 Months Ended

Dec. 31, 2015

Fair Value Disclosures [Abstract]

Schedule of Fair Value of Financial Assets

The following table sets forth the fair value of the financial assets that the Company re-measures on a regular basis:


	Level 1		Level 2		Level 3		Total
at December 31, 2015
Money market funds (a)	$	1.1	$	—	$	—	$	1.1
Corporate bonds and notes		—		59.6		—		59.6
Municipal bonds		—		66.5		—		66.5
Federal agency issues		—		44.3		—		44.3

Total	$	1.1	$	170.4	$	—	$	171.5

(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest


	Level 1		Level 2		Level 3		Total
at June 30, 2015
Money market funds (a)	$	2.4	$	—	$	—	$	2.4
Corporate bonds and notes		—		44.8		—		44.8
Municipal bonds		—		70.3		—		70.3
Federal agency issues		—		13.2		—		13.2

Total	$	2.4	$	128.3	$	—	$	130.7

(a)	Money market funds are primarily comprised of exchange traded funds and accrued interest

XML 43 R32.htm IDEA: XBRL DOCUMENT

Employee Deferred Savings Plan (Tables)

6 Months Ended

Dec. 31, 2015

Postemployment Benefits [Abstract]

Recorded Contributions to Employee Deferred Savings Plan

The Company’s recorded contributions to the plan as follows:


	Three months ended December 31,				Six months ended December 31,
	2015		2014		2015		2014
Deferred savings plan Company contributions	$	1.2	$	1.1	$	2.7	$	2.5

XML 44 R33.htm IDEA: XBRL DOCUMENT

Segment and Related Information (Tables)

6 Months Ended

Dec. 31, 2015

Segment Reporting [Abstract]

Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense

Segment revenue and operating income (loss) were as follows during the periods presented:


	Diagnostics		Other			Total
Three months ended December 31, 2015
Revenues	$	182.6	$	10.7		$	193.3
Depreciation and amortization		5.5		1.3			6.8
Segment operating income (loss)		64.6		(19.4	)		45.2
Three months ended December 31, 2014
Revenues	$	179.2	$	5.2		$	184.4
Depreciation and amortization		5.0		1.0			6.0
Segment operating income (loss)		59.0		(22.7	)		36.3
Six months ended December 31, 2015
Revenues	$	354.5	$	22.3		$	376.8
Depreciation and amortization		10.9		2.6			13.5
Segment operating income (loss)		127.0		(38.5	)		88.5
Six months ended December 31, 2014
Revenues	$	343.6	$	9.6		$	353.2
Depreciation and amortization		10.0		2.0			12.0
Segment operating income (loss)		104.1		(41.8	)		62.3


	Three months ended December 31,					Six months ended December 31,
	2015			2014		2015			2014
Total operating income for reportable segments	$	45.2		$	36.3	$	88.5		$	62.3
Unallocated amounts:
Interest income		0.1			0.1		0.2			0.1
Other		(0.3	)		1.5		(0.1	)		1.4

Income from operations before income taxes		45.0			37.9		88.6			63.8

Income tax provision		14.7			13.9		31.6			23.8

Net income	$	30.3		$	24.0	$	57.0		$	40.0

XML 45 R34.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information (Tables)

6 Months Ended

Dec. 31, 2015

Supplemental Cash Flow Elements [Abstract]

Schedule of Supplemental Cash Flow Information


	Six months ended December 31,
	2015			2014
Cash paid during the period for income taxes	$	28.5		$	12.8
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders’ equity	$	(0.2	)	$	(0.1	)

XML 46 R35.htm IDEA: XBRL DOCUMENT

Acquisitions - Additional Information (Detail) - German Clinic [Member] - USD ($) $ in Millions		6 Months Ended
	Feb. 27, 2015	Dec. 31, 2015
Business Acquisition [Line Items]
Total consideration transferred	$ 20.1
Intangible asset amortization period for income tax purposes		15 years

XML 47 R36.htm IDEA: XBRL DOCUMENT

Acquisitions - Allocation of Consideration Transferred (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015	Feb. 27, 2015
Business Acquisition [Line Items]
Goodwill	$ 177.0	$ 177.2
German Clinic [Member]
Business Acquisition [Line Items]
Current assets			$ 3.1
Real property			20.7
Equipment			1.6
Goodwill			8.1
Current liabilities			(4.4)
Long-term liabilities			(9.0)
Total purchase price			$ 20.1

XML 48 R37.htm IDEA: XBRL DOCUMENT

Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	$ 134.7	$ 64.1	$ 59.7	$ 64.8
Gross unrealized holding gains	0.1	0.1
Gross unrealized holding losses	(0.2)	(0.1)
Amortized cost	285.6	185.4
Estimated fair value	285.5	185.4
Corporate Bonds and Notes
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	45.5	41.8
Gross unrealized holding losses	(0.1)
Estimated fair value	45.4	41.8
Municipal Bonds
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	66.5	66.3
Gross unrealized holding gains	0.1	0.1
Gross unrealized holding losses	(0.1)	(0.1)
Estimated fair value	66.5	66.3
Federal Agency Issues
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	38.9	13.2
Estimated fair value	38.9	13.2
Cash
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	114.0	54.7
Estimated fair value	114.0	54.7
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	20.7	9.4
Estimated fair value	20.7	9.4
Total Cash and Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Amortized cost	134.7	64.1
Estimated fair value	$ 134.7	$ 64.1

XML 49 R38.htm IDEA: XBRL DOCUMENT

Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents, Amortized cost	$ 134.7	$ 64.1	$ 59.7	$ 64.8
Due within one year, Amortized cost	84.6
Due after one year through five years, Amortized cost	66.3
Due after five years, Amortized cost	0.0
Total	285.6	185.4
Due within one year, Estimated fair value	84.6
Due after one year through five years, Estimated fair value	66.2
Due after five years, Estimated fair value	0.0
Total	285.5	185.4
Cash
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents, Amortized cost	114.0	54.7
Cash equivalents, Estimated fair value	114.0	54.7
Cash Equivalents
Schedule of Available-for-sale Securities [Line Items]
Cash equivalents, Amortized cost	20.7	9.4
Cash equivalents, Estimated fair value	$ 20.7	$ 9.4

XML 50 R39.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Land	$ 2.3	$ 2.3
Buildings and improvements	17.3	18.2
Leasehold improvements	18.6	18.5
Equipment	101.0	99.1
Gross property, plant and equipment	139.2	138.1
Less accumulated depreciation	(77.5)	(70.9)
Property, plant and equipment, net	$ 61.7	$ 67.2

XML 51 R40.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 3.6	$ 2.9	$ 7.2	$ 5.5

XML 52 R41.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 177.0	$ 177.2
Diagnostics
Goodwill And Intangible Assets [Line Items]
Goodwill	112.3
Other
Goodwill And Intangible Assets [Line Items]
Goodwill	$ 64.7

XML 53 R42.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) $ in Millions	6 Months Ended
	Dec. 31, 2015 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Beginning balance	$ 177.2
Acquisitions	0.0
Translation adjustments	(0.2)
Ending balance	$ 177.0

XML 54 R43.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	$ 206.8	$ 206.8
Gross Carrying Amount, total intangible assets	211.6	211.6
Accumulated Amortization	(25.3)	(19.0)
Net, amortizable intangible assets	181.5	187.8
Net, total intangible assets	186.3	192.6
Net, non-amortizable intangible assets	4.8	4.8
In-Process Research and Development
Intangible Assets [Line Items]
Net, non-amortizable intangible assets	4.8	4.8
Purchased Licenses and Technologies
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	199.1	199.1
Accumulated Amortization	(22.6)	(16.7)
Net, amortizable intangible assets	176.5	182.4
Customer Relationships
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	4.7	4.7
Accumulated Amortization	(2.2)	(1.9)
Net, amortizable intangible assets	2.5	2.8
Trademarks
Intangible Assets [Line Items]
Gross Carrying Amount, amortizable intangible assets	3.0	3.0
Accumulated Amortization	(0.5)	(0.4)
Net, amortizable intangible assets	$ 2.5	$ 2.6

XML 55 R44.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 3.2	$ 3.1	$ 6.3	$ 6.5

XML 56 R45.htm IDEA: XBRL DOCUMENT

Cost Basis Investment - Additional Information (Detail) - RainDance	6 Months Ended
	Dec. 31, 2015 USD ($)
Schedule of Cost-method Investments [Line Items]
Investment accounted under cost method	$ 5,000,000
Impairment on investment	$ 0

XML 57 R46.htm IDEA: XBRL DOCUMENT

Accrued Liabilities - Summary of Accrued Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 34.4	$ 33.8
Accrued taxes payable	4.7	3.8
Other	8.8	8.5
Total Accrued liabilities	$ 47.9	$ 46.1

XML 58 R47.htm IDEA: XBRL DOCUMENT

Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) - USD ($) $ in Millions	Dec. 31, 2015	Jun. 30, 2015
Other Liabilities Disclosure [Abstract]
Pension obligation	$ 4.8	$ 4.9
Other	2.0	3.9
Total other long term liabilities	$ 6.8	$ 8.8

XML 59 R48.htm IDEA: XBRL DOCUMENT

Other Long Term Liabilities - Additional Information (Detail) $ in Millions	Dec. 31, 2015 USD ($) plan	Jun. 30, 2015 USD ($)
Other Liabilities Disclosure [Abstract]
Number of defined benefit pension plans \| plan	2
Fair value of plan assets	$ 0.2
Net pension liability	$ 4.8	$ 4.9

XML 60 R49.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity - Additional Information (Detail) - USD ($)	Dec. 31, 2015	Jun. 30, 2015	Feb. 28, 2015	Dec. 31, 2014	Jun. 30, 2014
Class of Stock [Line Items]
Preferred stock, shares authorized	5,000,000
Preferred stock, par value	$ 0.01
Preferred stock, shares outstanding	0
Common stock, shares authorized	150,000,000
Common stock, par value	$ 0.01
Common stock, shares issued	71,600,000	68,900,000		71,500,000	73,500,000
Common stock, shares outstanding	71,600,000	68,900,000		71,500,000	73,500,000
Share repurchase program, remaining authorized repurchase amount	$ 91,600,000
Seventh Share Repurchase Program
Class of Stock [Line Items]
Share repurchase program, authorized amount			$ 200,000,000

XML 61 R50.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) - shares shares in Millions	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Common stock issued, Beginning balance	68.9	73.5
Common stock outstanding, Beginning balance	68.9	73.5
Common stock issued upon exercise of options and employee stock plans	4.4	1.0
Repurchase and retirement of common stock	(1.7)	(3.0)
Common stock issued, Ending balance	71.6	71.5
Common stock outstanding, Ending balance	71.6	71.5

XML 62 R51.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) - shares shares in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Equity [Abstract]
Weighted-average shares outstanding used to compute basic EPS	70.5	72.5	69.6	72.6
Effect of dilutive shares	3.3	2.9	3.5	3.2
Weighted-average shares outstanding and dilutive securities used to compute diluted EPS	73.8	75.4	73.1	75.8

XML 63 R52.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) shares in Millions	3 Months Ended
	Dec. 31, 2014 shares
Equity [Abstract]
Anti-dilutive options and RSU's excluded from EPS computation	0.9

XML 64 R53.htm IDEA: XBRL DOCUMENT

Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Stockholders Equity [Line Items]
Shares purchased and retired			1.7	3.0
Common stock and additional paid-in-capital reductions	$ 5.4	$ 14.8	$ 14.9	$ 25.0
Charges to retained earnings	$ 20.0	$ 43.6	$ 48.5	$ 79.0
Common Stock
Stockholders Equity [Line Items]
Shares purchased and retired	0.6	1.7	1.7	3.0

XML 65 R54.htm IDEA: XBRL DOCUMENT

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income tax expense	$ 14.7	$ 13.9	$ 31.6	$ 23.8
Approximate rate on pre-tax income	33.00%	37.00%	36.00%	37.00%
U.S. federal statutory rate	35.00%		35.00%
Non-current deferred tax assets	$ 13.5		$ 13.5

XML 66 R55.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Sep. 30, 2014	Dec. 31, 2015	Dec. 30, 2015	Dec. 03, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized share-based compensation cost related to stock options		$ 10.8
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years		4 years
Total unrecognized share-based compensation cost, weighted-average period, years		1 year 4 months 2 days
Stock options \| Share-based compensation granted after December 5, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		8 years
Stock options \| Share-based compensation granted prior to December 5, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expire from date of grant, years		10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Service period of share-based compensation vested, years	4 years
Total unrecognized share-based compensation cost, weighted-average period, years		2 years 9 months 15 days
Total unrecognized share-based compensation cost related to RSUs		$ 39.0
The 2010 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved				1,600,000
Shares reserved for issuance exercise of options			2,300,000
The 2010 Plan \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future grant		2,500,000
2012 Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares approved		2,000,000
Shares issued under the Plan		700,000

XML 67 R56.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) shares in Millions	6 Months Ended
	Dec. 31, 2015 $ / shares shares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Options outstanding at beginning of period, Number of shares \| shares	12.5
Options granted, Number of shares \| shares	0.0
Options exercised, Number of shares \| shares	(4.0)
Options canceled or expired, Number of shares \| shares	0.0
Options outstanding at end of year, Number of shares \| shares	8.5
Options exercisable at end of period, Number of shares \| shares	6.9
Options outstanding at beginning of period, Weighted average exercise price \| $ / shares	$ 23.49
Options granted, Weighted average exercise price \| $ / shares	0
Options exercised, Weighted average exercise price \| $ / shares	21.38
Options canceled or expired, Weighted average exercise price \| $ / shares	0
Options outstanding at end of year, Weighted average exercise price \| $ / shares	24.50
Options exercisable at end of period, Weighted average exercise price \| $ / shares	$ 24.00

XML 68 R57.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) - Restricted Stock Units (RSUs) shares in Millions	6 Months Ended
	Dec. 31, 2015 $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
RSUs outstanding at beginning of period, Number of shares \| shares	1.0
RSUs granted, Number of shares \| shares	0.8
RSUs vested, Number of shares \| shares	(0.3)
RSUs canceled, Number of shares \| shares	0.0
RSUs outstanding at end of period, Number of shares \| shares	1.5
RSUs outstanding at beginning of period, Weighted average grant date fair value \| $ / shares	$ 37.63
RSUs granted, Weighted average grant date fair value \| $ / shares	40.66
RSUs vested, Weighted average grant date fair value \| $ / shares	39.74
RSUs canceled, Weighted average grant date fair value \| $ / shares	0
RSUs outstanding at end of period, Weighted average grant date fair value \| $ / shares	$ 38.80

XML 69 R58.htm IDEA: XBRL DOCUMENT

Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 7.7	$ 12.1	$ 16.3	$ 19.0
Molecular Diagnostic Testing Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.3	0.2	0.5	0.4
Pharmaceutical and Clinical Services Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	0.1	0.1	0.2	0.3
Research And Development Expense
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	1.2	1.3	2.8	2.0
Selling, General, and Administrative Expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense	$ 6.1	$ 10.5	$ 12.8	$ 16.3

XML 70 R59.htm IDEA: XBRL DOCUMENT

Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) - USD ($)
$ in Millions

Dec. 31, 2015

Jun. 30, 2015

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

$ 171.5

$ 130.7

Money Market Funds

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

^[1]

1.1

2.4

Corporate Bonds and Notes

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

59.6

44.8

Municipal Bonds

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

66.5

70.3

Federal Agency Issues

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

44.3

13.2

Level 1

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

1.1

2.4

Level 1 | Money Market Funds

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

^[1]

1.1

2.4

Level 2

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

170.4

128.3

Level 2 | Corporate Bonds and Notes

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

59.6

44.8

Level 2 | Municipal Bonds

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

66.5

70.3

Level 2 | Federal Agency Issues

Fair Value, Option, Qualitative Disclosures Related to Election [Line Items]

Total fair value of financial assets

$ 44.3

$ 13.2

[1]	Money market funds are primarily comprised of exchange traded funds and accrued interest

XML 71 R60.htm IDEA: XBRL DOCUMENT

Employee Deferred Savings Plan - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Percent of employee contribution to deferred savings plan	50.00%
Employer's contribution not to exceed percentage of the employees compensation	4.00%

XML 72 R61.htm IDEA: XBRL DOCUMENT

Employee Deferred Savings Plan - Company's Recorded Contributions To Plan (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Compensation and Retirement Disclosure [Abstract]
Deferred savings plan Company contributions	$ 1.2	$ 1.1	$ 2.7	$ 2.5

XML 73 R62.htm IDEA: XBRL DOCUMENT

Segment and Related Information - Additional Information (Detail)	6 Months Ended
	Dec. 31, 2015 Segment
Segment Reporting [Abstract]
Number of reportable segment	2

XML 74 R63.htm IDEA: XBRL DOCUMENT

Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting Information [Line Items]
Revenues	$ 193.3	$ 184.4	$ 376.8	$ 353.2
Depreciation and amortization	6.8	6.0	13.5	12.0
Segment operating income (loss)	45.2	36.3	88.5	62.3
Diagnostics
Segment Reporting Information [Line Items]
Revenues	182.6	179.2	354.5	343.6
Depreciation and amortization	5.5	5.0	10.9	10.0
Segment operating income (loss)	64.6	59.0	127.0	104.1
Other
Segment Reporting Information [Line Items]
Revenues	10.7	5.2	22.3	9.6
Depreciation and amortization	1.3	1.0	2.6	2.0
Segment operating income (loss)	$ (19.4)	$ (22.7)	$ (38.5)	$ (41.8)

XML 75 R64.htm IDEA: XBRL DOCUMENT

Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Segment Reporting [Abstract]
Total operating income for reportable segments	$ 45.2	$ 36.3	$ 88.5	$ 62.3
Interest income	0.1	0.1	0.2	0.1
Other	(0.3)	1.5	(0.1)	1.4
Income before income tax	45.0	37.9	88.6	63.8
Income tax provision	14.7	13.9	31.6	23.8
Net income	$ 30.3	$ 24.0	$ 57.0	$ 40.0

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 76 R65.htm IDEA: XBRL DOCUMENT

Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash paid during the period for income taxes	$ 28.5	$ 12.8
Non-cash investing and financing activities:
Fair value adjustment on marketable investment securities recorded to stockholders' equity	$ (0.2)	$ (0.1)

EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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~~F)Z_FL_CWLUJ4_4P,OBO]AM>UTLL(T"V[7 /KG>Y#ZFC!@9,'D2GOM& M^1>C_,HHO6F4KXR^6I!5\P3H-IQ1@RHU2!M[MU27:_"~~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�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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.1.900 html 97 225 1 true 33 0 false 6 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.myriad.com/taxonomy/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.myriad.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.myriad.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 105 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.myriad.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 106 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.myriad.com/taxonomy/role/StatementOfOtherComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 5 false false R6.htm 107 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.myriad.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 108 - Disclosure - Basis of Presentation Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation Notes 7 false false R8.htm 109 - Disclosure - Acquisitions Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock Acquisitions Notes 8 false false R9.htm 110 - Disclosure - Marketable Investment Securities Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Marketable Investment Securities Notes 9 false false R10.htm 111 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock Property, Plant and Equipment, Net Notes 10 false false R11.htm 112 - Disclosure - Goodwill and Intangible Assets Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock Goodwill and Intangible Assets Notes 11 false false R12.htm 113 - Disclosure - Cost Basis Investment Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCostMethodInvestmentsDescriptionTextBlock Cost Basis Investment Notes 12 false false R13.htm 114 - Disclosure - Accrued Liabilities Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Liabilities Notes 13 false false R14.htm 115 - Disclosure - Other Long Term Liabilities Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock Other Long Term Liabilities Notes 14 false false R15.htm 116 - Disclosure - Preferred and Common Stockholder's Equity Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Preferred and Common Stockholder's Equity Notes 15 false false R16.htm 117 - Disclosure - Income Taxes Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock Income Taxes Notes 16 false false R17.htm 118 - Disclosure - Share-Based Compensation Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Share-Based Compensation Notes 17 false false R18.htm 119 - Disclosure - Fair Value Measurements Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value Measurements Notes 18 false false R19.htm 120 - Disclosure - Commitment and Contingencies Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitment and Contingencies Notes 19 false false R20.htm 121 - Disclosure - Employee Deferred Savings Plan Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock Employee Deferred Savings Plan Notes 20 false false R21.htm 122 - Disclosure - Segment and Related Information Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock Segment and Related Information Notes 21 false false R22.htm 123 - Disclosure - Supplemental Cash Flow Information Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock Supplemental Cash Flow Information Notes 22 false false R23.htm 124 - Disclosure - Acquisitions (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables Acquisitions (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock 23 false false R24.htm 125 - Disclosure - Marketable Investment Securities (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlockTables Marketable Investment Securities (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock 24 false false R25.htm 126 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables Property, Plant and Equipment, Net (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock 25 false false R26.htm 127 - Disclosure - Goodwill and Intangible Assets (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlockTables Goodwill and Intangible Assets (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsGoodwillAndIntangibleAssetsDisclosureTextBlock 26 false false R27.htm 128 - Disclosure - Accrued Liabilities (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Liabilities (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock 27 false false R28.htm 129 - Disclosure - Other Long Term Liabilities (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlockTables Other Long Term Liabilities (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsOtherLiabilitiesDisclosureTextBlock 28 false false R29.htm 130 - Disclosure - Preferred and Common Stockholder's Equity (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Preferred and Common Stockholder's Equity (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock 29 false false R30.htm 131 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Share-Based Compensation (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock 30 false false R31.htm 132 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables Fair Value Measurements (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock 31 false false R32.htm 133 - Disclosure - Employee Deferred Savings Plan (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlockTables Employee Deferred Savings Plan (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCompensationAndEmployeeBenefitPlansTextBlock 32 false false R33.htm 134 - Disclosure - Segment and Related Information (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables Segment and Related Information (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock 33 false false R34.htm 135 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlockTables Supplemental Cash Flow Information (Tables) Tables http://www.myriad.com/taxonomy/role/NotesToFinancialStatementsCashFlowSupplementalDisclosuresTextBlock 34 false false R35.htm 136 - Disclosure - Acquisitions - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureAcquisitionsAdditionalInformation Acquisitions - Additional Information (Detail) Details 35 false false R36.htm 137 - Disclosure - Acquisitions - Allocation of Consideration Transferred (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureAcquisitionsAllocationOfConsiderationTransferred Acquisitions - Allocation of Consideration Transferred (Detail) Details 36 false false R37.htm 138 - Disclosure - Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureMarketableInvestmentSecuritiesScheduleOfFairValueForAvailableforSaleSecuritiesByMajorSecurityTypeAndClassOfSecurity Marketable Investment Securities - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Detail) Details 37 false false R38.htm 139 - Disclosure - Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureMarketableInvestmentSecuritiesScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsCashEquivalentsAndAvailableForSaleSecurities Marketable Investment Securities - Schedule of Maturities of Debt Securities Classified as Cash Equivalents and Available-For-Sale Securities (Detail) Details 38 false false R39.htm 140 - Disclosure - Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetScheduleOfPropertyPlantAndEquipmentNet Property, Plant and Equipment, Net - Schedule of Property, Plant and Equipment, Net (Detail) Details 39 false false R40.htm 141 - Disclosure - Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetScheduleOfDepreciationExpense Property, Plant and Equipment, Net - Schedule of Depreciation Expense (Detail) Details 40 false false R41.htm 142 - Disclosure - Goodwill and Intangible Assets - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformation Goodwill and Intangible Assets - Additional Information (Detail) Details 41 false false R42.htm 143 - Disclosure - Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummaryOfChangesToGoodwillBalance Goodwill and Intangible Assets - Summary of Changes to Goodwill Balance (Detail) Details 42 false false R43.htm 144 - Disclosure - Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsSummarizedAmountsReportedAsIntangibleAssets Goodwill and Intangible Assets - Summarized Amounts Reported as Intangible Assets (Detail) Details 43 false false R44.htm 145 - Disclosure - Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAmortizationOnIntangibleAssets Goodwill and Intangible Assets - Amortization on Intangible Assets (Detail) Details 44 false false R45.htm 146 - Disclosure - Cost Basis Investment - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureCostBasisInvestmentAdditionalInformation Cost Basis Investment - Additional Information (Detail) Details 45 false false R46.htm 147 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilities Accrued Liabilities - Summary of Accrued Liabilities (Detail) Details 46 false false R47.htm 148 - Disclosure - Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureOtherLongTermLiabilitiesSummaryOfOtherLongTermLiabilities Other Long Term Liabilities - Summary of Other Long Term Liabilities (Detail) Details 47 false false R48.htm 149 - Disclosure - Other Long Term Liabilities - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureOtherLongTermLiabilitiesAdditionalInformation Other Long Term Liabilities - Additional Information (Detail) Details 48 false false R49.htm 150 - Disclosure - Preferred and Common Stockholder's Equity - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePreferredAndCommonStockholdersEquityAdditionalInformation Preferred and Common Stockholder's Equity - Additional Information (Detail) Details 49 false false R50.htm 151 - Disclosure - Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePreferredAndCommonStockholdersEquitySummaryOfCommonSharesIssuedAndOutstanding Preferred and Common Stockholder's Equity - Summary of Common Shares Issued and Outstanding (Detail) Details 50 false false R51.htm 152 - Disclosure - Preferred and Common Stockholder's Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePreferredAndCommonStockholdersEquityReconciliationOfDenominatorsOfBasicAndDilutedEarningsPerShareComputations Preferred and Common Stockholder's Equity - Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Detail) Details 51 false false R52.htm 153 - Disclosure - Preferred and Common Stockholder's Equity - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePreferredAndCommonStockholdersEquityScheduleOfAntiDilutiveOptionsAndRestrictedStockUnitsExcludedFromEPSComputation Preferred and Common Stockholder's Equity - Schedule of Anti-Dilutive Options and Restricted Stock Units Excluded from EPS Computation (Detail) Details 52 false false R53.htm 154 - Disclosure - Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosurePreferredAndCommonStockholdersEquityScheduleOfStockRepurchases Preferred and Common Stockholder's Equity - Schedule of Stock Repurchases (Detail) Details 53 false false R54.htm 155 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation Income Taxes - Additional Information (Detail) Details 54 false false R55.htm 156 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureShareBasedCompensationAdditionalInformation Share-Based Compensation - Additional Information (Detail) Details 55 false false R56.htm 157 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstanding Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding (Detail) Details 56 false false R57.htm 158 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsOutstanding Share-Based Compensation - Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding (Detail) Details 57 false false R58.htm 159 - Disclosure - Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureShareBasedCompensationScheduleOfShareBasedCompensationRecognizedInConsolidatedStatementsOfOperations Share-Based Compensation - Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations (Detail) Details 58 false false R59.htm 160 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfFairValueOfFinancialAssets Fair Value Measurements - Schedule of Fair Value of Financial Assets (Detail) Details 59 false false R60.htm 161 - Disclosure - Employee Deferred Savings Plan - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureEmployeeDeferredSavingsPlanAdditionalInformation Employee Deferred Savings Plan - Additional Information (Detail) Details 60 false false R61.htm 162 - Disclosure - Employee Deferred Savings Plan - Company's Recorded Contributions To Plan (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureEmployeeDeferredSavingsPlanCompanysRecordedContributionsToPlan Employee Deferred Savings Plan - Company's Recorded Contributions To Plan (Detail) Details 61 false false R62.htm 163 - Disclosure - Segment and Related Information - Additional Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureSegmentAndRelatedInformationAdditionalInformation Segment and Related Information - Additional Information (Detail) Details 62 false false R63.htm 164 - Disclosure - Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureSegmentAndRelatedInformationScheduleOfSegmentPerformanceBasedOnIncomeLossBeforeInterestIncomeAndOtherIncomeAndExpense Segment and Related Information - Schedule of Segment Performance Based on Income (Loss) before Interest Income and Other Income and Expense (Detail) Details 63 false false R64.htm 165 - Disclosure - Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureSegmentAndRelatedInformationScheduleOfTotalOperatingIncomeForReportableSegments Segment and Related Information - Schedule of Total Operating Income for Reportable Segments (Detail) Details 64 false false R65.htm 166 - Disclosure - Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) Sheet http://www.myriad.com/taxonomy/role/DisclosureSupplementalCashFlowInformationScheduleOfSupplementalCashFlowInformation Supplemental Cash Flow Information - Schedule of Supplemental Cash Flow Information (Detail) Details 65 false false All Reports Book All Reports mygn-20151231.xml mygn-20151231.xsd mygn-20151231_cal.xml mygn-20151231_def.xml mygn-20151231_lab.xml mygn-20151231_pre.xml true true ZIP 83 0001193125-16-448574-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-16-448574-xbrl.zip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end

Large accelerated filer

Accelerated filer

Non-accelerated filer

¨ (Do not check if smaller reporting company)

Smaller reporting company